id,generic_name,company_name,presentation,update_type,update_date,availability,related_info,resolved_note,reason_for_shortage,therapeutic_category,status,change_date,date_discontinued
13405,Acyclovir Ointment,"Mylan Institutional, a Viatris Company","Acyclovir Ointment 5% 15gram Tube, Ointment, 5% 15gram (NDC 0378-8700-06)",New,9/16/24,,,,,Dermatology,To Be Discontinued,,9/16/24
13406,Acyclovir Ointment,"Mylan Institutional, a Viatris Company","Acyclovir Ointment 5% 5g 2pk, Ointment, 5% 5g (NDC 51079-550-68)",New,9/16/24,,,,,Dermatology,To Be Discontinued,,9/16/24
13407,Acyclovir Ointment,"Actavis Pharma, Inc.","Zovirax, Ointment, 50 mg/1 g (NDC 0591-1159-30)",New,3/3/25,,,,,Dermatology,To Be Discontinued,,3/3/25
13408,Adalimumab-adaz Injection,Sandoz Inc.,"Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-20)",New,4/14/25,,,,,Rheumatology,To Be Discontinued,,4/14/25
13409,Adalimumab-adaz Injection,Sandoz Inc.,"Hyrimoz, Injection, 20 mg/.2 mL (NDC 61314-476-64)",New,4/14/25,,,,,Rheumatology,To Be Discontinued,,4/14/25
13410,Adalimumab-adaz Injection,Sandoz Inc.,"Hyrimoz, Injection, 10 mg/.1 mL (NDC 61314-509-64)",New,4/14/25,,,,,Rheumatology,To Be Discontinued,,4/14/25
13411,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0375-16)",New,3/3/25,,,,,Rheumatology,To Be Discontinued,,3/3/25
13412,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0375-23)",New,3/3/25,,,,,Rheumatology,To Be Discontinued,,3/3/25
13413,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0495-40)",New,1/6/25,,,,,Rheumatology,To Be Discontinued,,1/6/25
13414,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0495-60)",New,1/6/25,,,,,Rheumatology,To Be Discontinued,,1/6/25
13415,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0575-40)",New,1/6/25,,,,,Rheumatology,To Be Discontinued,,1/6/25
13416,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0575-60)",New,1/6/25,,,,,Rheumatology,To Be Discontinued,,1/6/25
13417,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0545-44)",New,1/6/25,,,,,Rheumatology,To Be Discontinued,,1/6/25
13418,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0545-66)",New,1/6/25,,,,,Rheumatology,To Be Discontinued,,1/6/25
13419,Adefovir Dipivoxil Tablet,Apotex Corp.,"Adefovir Dipivoxil, Tablet, 10 mg (NDC 60505-3947-3)",New,7/29/25,,Discontinuation of the manufacture of the drug,,,Antiviral,To Be Discontinued,,7/29/25
13420,Albendazole Tablet,Strides Pharma Inc.,"Tablet, 200 mg (NDC 31722-935-02)",New,9/16/24,,Current Product distributor: Camber Pharmaceuticals. Product temporarily discontinued due to business related reasons.,,,Anti-Infective,To Be Discontinued,,9/16/24
13421,Albuterol Sulfate Solution,Nephron Pharmaceuticals Corporation,"Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 0487-9901-30)",Revised,7/2/25,Available,"Albuterol 0.5% is in stock, though demand remains high; additional supply can be produced as needed.",,Other,Pulmonary/Allergy; Pediatric,Current,,
13422,Albuterol Sulfate Solution,"Rising Pharma Holdings, Inc.","Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 64980-642-03)",Reverified,8/15/25,Available,,,,Pediatric; Pulmonary/Allergy,Current,,
13423,Albuterol Sulfate Solution,"Ritedose Pharmaceuticals, LLC","Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 76204-027-01)",Reverified,8/15/25,Available,,,,Pediatric; Pulmonary/Allergy,Current,,
13424,Albuterol Sulfate Syrup,"Actavis Pharma, Inc.","Syrup, 2 mg/5 mL (NDC 0472-0825-16)",New,11/4/24,,,,,Pulmonary/Allergy,To Be Discontinued,,11/4/24
13425,Amantadine Hydrochloride Capsule,"Teva Pharmaceuticals USA, Inc.","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0591-4920-01)",New,2/5/25,,A business decision was made to discontinue manufacture of the drug.,,,Antiviral; Neurology,To Be Discontinued,,2/5/25
13426,Amantadine Hydrochloride Capsule,"Teva Pharmaceuticals USA, Inc.","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0591-4920-05)",New,2/5/25,,A business decision was made to discontinue manufacture of the drug.,,,Antiviral; Neurology,To Be Discontinued,,2/5/25
13427,Amantadine Hydrochloride Capsule,Strides Pharma Inc.,"Amantadine Hydrochloride, Capsule, 100 mg (NDC 42543-493-01)",New,2/12/25,,Discontinuation of manufacture of drug based on business decision,,,Antiviral; Neurology,To Be Discontinued,,2/12/25
13428,Amantadine Hydrochloride Capsule,Strides Pharma Inc.,"Amantadine Hydrochloride, Capsule, 100 mg (NDC 42543-493-05)",New,2/12/25,,Discontinuation of manufacture of drug based on business decision,,,Antiviral; Neurology,To Be Discontinued,,2/12/25
13429,Amantadine Hydrochloride Capsule,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0832-1015-00)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/25
13430,Amantadine Hydrochloride Capsule,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0832-1015-50)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/25
13431,Amantadine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-00)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/25
13432,Amantadine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-03)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/25
13433,Amantadine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-50)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/25
13434,Ambrisentan Tablet,Apotex Corp.,"Ambrisentan, Tablet, 5 mg (NDC 60505-4552-3)",New,1/14/25,,,,,Cardiovascular,To Be Discontinued,,1/14/25
13435,Ambrisentan Tablet,Apotex Corp.,"Ambrisentan, Tablet, 10 mg (NDC 60505-4553-3)",New,1/14/25,,,,,Cardiovascular,To Be Discontinued,,1/14/25
13436,Amino Acid Injection,Baxter Healthcare,"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)",Reverified,9/3/25,Available,,,,Gastroenterology,Current,,
13437,Amino Acid Injection,Baxter Healthcare,"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)",Reverified,9/3/25,Available,,,,Gastroenterology,Current,,
13438,Amino Acid Injection,Baxter Healthcare,"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)",Reverified,9/3/25,Available,,,,Gastroenterology,Current,,
13439,Amino Acid Injection,Baxter Healthcare,"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)",Reverified,9/3/25,Available,,,,Gastroenterology,Current,,
13440,Amino Acid Injection,Baxter Healthcare,"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)",Revised,9/3/25,Limited Availability,Capacity constraint - Recovery in November 2025,,Other,Gastroenterology,Current,,
13441,Amino Acid Injection,Baxter Healthcare,"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)",Reverified,9/3/25,Unavailable,Capacity constraint - Recovery in October 2025,,Other,Gastroenterology,Current,,
13442,Amino Acid Injection,Baxter Healthcare,"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)",Reverified,9/3/25,Available,,,,Gastroenterology,Current,,
13443,Amino Acid Injection,B. Braun Medical Inc.,"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)",Reverified,8/21/25,Available,On allocation. Manufacturing delay.,,Other,Gastroenterology,Current,,
13444,Amino Acid Injection,B. Braun Medical Inc.,"Plenamine, Injection, 0.15 (NDC 0264-4500-05)",Reverified,8/21/25,Available,On allocation. Manufacturing delay.,,Other,Gastroenterology,Current,,
13445,Amino Acid Injection,Baxter Healthcare,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)",Reverified,9/3/25,Available,,,,Gastroenterology,Current,,
13446,Amino Acid Injection,B. Braun Medical Inc.,"Plenamine, Injection, 0.15 (NDC 0264-4500-00)",Reverified,8/21/25,Available,On allocation. Manufacturing delay.,,Other,Gastroenterology,Current,,
13447,Amino Acid Injection,Otsuka ICU Medical LLC,"Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Gastroenterology,Current,,
13448,Amino Acid Injection,Otsuka ICU Medical LLC,"Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Gastroenterology,Current,,
13449,Amino Acid Injection,Otsuka ICU Medical LLC,"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)",Reverified,8/20/25,Unavailable,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Shortage of an active ingredient,Gastroenterology,Current,,
13450,Amino Acid Injection,Otsuka ICU Medical LLC,"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)",Reverified,8/20/25,Unavailable,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Shortage of an active ingredient,Gastroenterology,Current,,
13451,Amino Acid Injection,Baxter Healthcare,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)",Reverified,9/3/25,Available,,,,Gastroenterology,Current,,
13452,Aminocaproic Acid Tablet,ANI Pharmaceuticals,"Tablet, 500 mg (NDC 62559-225-30)",New,11/7/24,,"ANI anticipates ceasing distribution on November 30, 2024.",,,Cardiovascular; Hematology; Other,To Be Discontinued,,11/7/24
13453,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 2.5 mg; 10 mg (NDC 65862-582-01)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25
13454,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 10 mg (NDC 65862-583-01)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25
13455,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 10 mg (NDC 65862-583-05)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25
13456,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 20 mg (NDC 65862-584-01)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25
13457,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 20 mg (NDC 65862-584-05)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25
13458,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 40 mg (NDC 65862-585-01)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25
13459,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 40 mg (NDC 65862-585-05)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25
13460,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 20 mg (NDC 65862-586-01)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25
13461,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 20 mg (NDC 65862-586-05)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25
13462,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 40 mg (NDC 65862-587-01)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25
13463,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Novartis Pharmaceuticals Corporation,"Lotrel, Capsule, 10 mg; 20 mg (NDC 0078-0364-05)",New,6/24/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/24/25
13464,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Novartis Pharmaceuticals Corporation,"Lotrel, Capsule, 10 mg; 40 mg (NDC 0078-0379-05)",New,6/24/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/24/25
13465,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Novartis Pharmaceuticals Corporation,"Lotrel, Capsule, 5 mg; 10 mg (NDC 0078-0405-05)",New,6/24/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/24/25
13466,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Novartis Pharmaceuticals Corporation,"Lotrel, Capsule, 5 mg; 20 mg (NDC 0078-0406-05)",New,6/24/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/24/25
13467,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-05)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13468,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-30)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13469,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-90)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13470,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-05)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13471,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-30)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13472,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-90)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13473,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-05)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13474,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-30)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13475,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-90)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13476,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-05)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13477,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-30)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13478,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-90)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13479,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-05)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13480,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-30)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13481,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-90)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25
13482,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-73)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13483,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-76)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13484,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-78)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13485,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-73)",Revised,5/2/25,,,Available,,Anti-Infective,Resolved,5/2/25,
13486,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-76)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13487,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-78)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13488,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-55)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13489,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-80)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13490,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-50)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13491,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-75)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13492,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-55)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13493,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-80)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13494,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-50)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13495,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-75)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13496,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-15)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13497,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-80)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13498,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-50)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13499,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-75)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13500,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-15)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13501,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-80)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13502,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-50)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13503,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-75)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13504,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13505,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13506,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13507,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13508,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13509,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13510,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13511,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13512,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-46)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13513,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-55)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13514,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-58)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13515,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-46)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13516,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-52)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13517,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-57)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13518,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-46)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13519,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-52)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13520,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-57)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13521,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-46)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13522,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-55)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13523,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-58)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13524,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-73)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13525,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-80)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13526,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-79)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,
13527,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13528,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13529,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13530,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13531,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13532,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13533,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)",Reverified,9/2/25,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,
13534,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)",Reverified,9/2/25,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,
13535,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)",Reverified,9/2/25,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,
13536,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)",Reverified,9/2/25,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,
13537,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)",Reverified,9/2/25,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,
13538,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 47781-174-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13539,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 47781-176-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13540,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 47781-178-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13541,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 47781-179-01)",Reverified,9/2/25,Unavailable,Supporting contracted business only; Resupply Q3 2025,,Other,Psychiatry,Current,,
13542,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 47781-180-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13543,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
13544,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
13545,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
13546,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
13547,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
13548,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
13549,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
13550,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13551,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13552,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13553,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13554,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13555,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13556,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
13557,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)",Reverified,8/19/25,Available,,,,Psychiatry,Current,,
13558,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)",Revised,8/19/25,Limited Availability,Allocating to customers,,Other,Psychiatry,Current,,
13559,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)",Revised,8/19/25,Unavailable,Estimated availability October 2025,,Shortage of an active ingredient,Psychiatry,Current,,
13560,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)",Revised,8/19/25,Limited Availability,Allocating to customers,,Other,Psychiatry,Current,,
13561,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)",Revised,8/19/25,Limited Availability,Allocating to customers,,Other,Psychiatry,Current,,
13562,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)",Reverified,6/25/25,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,
13563,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)",Reverified,6/25/25,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,
13564,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)",Reverified,6/25/25,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,
13565,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)",Reverified,6/25/25,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,
13566,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)",Reverified,6/25/25,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,
13567,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)",Reverified,6/25/25,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,
13568,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)",Reverified,8/12/25,Available,,,,Psychiatry,Current,,
13569,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)",Reverified,8/12/25,Available,,,,Psychiatry,Current,,
13570,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)",Reverified,8/12/25,Available,,,,Psychiatry,Current,,
13571,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)",Reverified,8/12/25,Available,,,,Psychiatry,Current,,
13572,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)",Reverified,8/12/25,Available,,,,Psychiatry,Current,,
13573,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)",Reverified,8/12/25,Available,,,,Psychiatry,Current,,
13574,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)",Reverified,8/12/25,Available,,,,Psychiatry,Current,,
13575,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)",Reverified,9/2/25,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,
13576,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)",Reverified,9/2/25,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,
13577,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)",Reverified,9/2/25,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,
13578,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)",Reverified,9/2/25,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,
13579,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)",Reverified,9/2/25,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,
13580,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)",Reverified,9/2/25,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,
13581,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)",Reverified,9/2/25,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,
13582,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
13583,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
13584,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
13585,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
13586,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
13587,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
13588,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
13589,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
13590,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
13591,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
13592,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
13593,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)",Revised,8/19/25,Available,Estimated recovery: December 2025,,Other,Psychiatry,Current,,
13594,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
13595,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
13596,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)",Revised,8/19/25,Limited Availability,Estimated recovery: October 2025,,Other,Psychiatry,Current,,
13597,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)",Revised,8/19/25,Limited Availability,Estimated recovery: August 2025,,Other,Psychiatry,Current,,
13598,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)",Revised,8/19/25,Limited Availability,Estimated recovery: November 2025,,Other,Psychiatry,Current,,
13599,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
13600,Amphotericin B Injection,"Leadiant Biosciences, Inc.","Abelcet, Injection, 5 mg/1 mL; 3.4 mg/1 mL; 1.5 mg/1 mL (NDC 57665-101-41)",New,8/8/25,,Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,,8/8/25
13601,Atazanavir Sulfate Capsule,Bristol Myers Squibb Co.,"Reyataz, Capsule, 200 mg (NDC 0003-3631-12)",New,6/4/25,,Permanent discontinuation,,,Antiviral,To Be Discontinued,,6/4/25
13602,Atazanavir Sulfate Capsule,Bristol Myers Squibb Co.,"Reyataz, Capsule, 300 mg (NDC 0003-3622-12)",New,6/4/25,,Permanent discontinuation,,,Antiviral,To Be Discontinued,,6/4/25
13603,Atazanavir Sulfate Oral Powder,Bristol Myers Squibb Co.,"Reyataz, Oral Powder, 50 mg (NDC 0003-3638-10)",New,6/4/25,,Permanent discontinuation,,,Antiviral,To Be Discontinued,,6/4/25
13604,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 10 mg (NDC 0002-3227-30)",New,10/22/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/24
13605,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 25 mg (NDC 0002-3228-30)",New,10/22/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/24
13606,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 40 mg (NDC 0002-3229-30)",New,10/22/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/24
13607,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 18 mg (NDC 0002-3238-30)",New,10/22/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/24
13608,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 60 mg (NDC 0002-3239-30)",New,10/22/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/24
13609,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 80 mg (NDC 0002-3250-30)",New,10/22/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/24
13610,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 100 mg (NDC 0002-3251-30)",New,10/22/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/24
13611,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 0409-4910-34)",New,2/19/25,,,,,Anesthesia; Neurology; Pediatric,To Be Discontinued,,2/19/25
13612,Atropine Sulfate Injection,"Fresenius Kabi USA, LLC","Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Neurology; Pediatric,Current,,
13613,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc.","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)",Reverified,8/19/25,Available,,,,Anesthesia; Neurology; Pediatric,Current,,
13614,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology; Pediatric,Current,,
13615,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology; Pediatric,Current,,
13616,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, 0.5 mg/5 mL (0.1 mg/mL) Syringes (NDC 0409-4910-34)",Revised,8/19/25,Unavailable,Next Delivery and Estimated Recovery: December 2028,,Other,Anesthesia; Neurology; Pediatric,Current,,
13617,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-4911-34)",Revised,8/15/25,Unavailable.,Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Anesthesia; Neurology; Pediatric,Current,,
13618,Atropine Sulfate Injection,"American Regent, Inc.","Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)",Reverified,8/19/25,Available,old NDC 0517-1010-25,,,Anesthesia; Neurology; Pediatric,Current,,
13619,Atropine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)",Reverified,7/23/25,Available,,,,Anesthesia; Neurology; Pediatric,Current,,
13620,Atropine Sulfate Injection,"American Regent, Inc.","Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)",Reverified,8/19/25,Available,old NDC 0517-0401-25,,,Anesthesia; Neurology; Pediatric,Current,,
13621,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)",Revised,8/19/25,"Unavailable, 90 days",Manufacturing in process,,Requirements related to complying with good manufacturing practices,Anesthesia; Neurology; Pediatric,Current,,
13622,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)",Reverified,8/19/25,Unavailable,Resupply TBD,,Requirements related to complying with good manufacturing practices,Anesthesia; Neurology; Pediatric,Current,,
13623,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)",Revised,8/19/25,"Unavailable, 90 days",Manufacturing in process,,Requirements related to complying with good manufacturing practices,Anesthesia; Neurology; Pediatric,Current,,
13624,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)",Reverified,8/19/25,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia; Neurology; Pediatric,Current,,
13625,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)",Revised,8/19/25,"Unavailable, 90 days",Manufacturing in process,,Requirements related to complying with good manufacturing practices,Anesthesia; Neurology; Pediatric,Current,,
13626,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)",Reverified,8/19/25,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia; Neurology; Pediatric,Current,,
13627,Atropine Sulfate Injection,"Medefil, Inc.","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 64253-400-91)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology; Pediatric,Current,,
13628,Azacitidine Injection,Eugia US LLC,"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)",Reverified,8/21/25,Available,Check wholesalers for inventory,,,Oncology,Current,,
13629,Azacitidine Injection,"Meitheal Pharmaceuticals, Inc.","Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)",Reverified,8/19/25,Available,,,,Oncology,Current,,
13630,Azacitidine Injection,Bristol Myers Squibb Co.,"Vidaza, Injection, 100 mg (NDC 59572-102-01)",Reverified,9/3/25,Available,,,,Oncology,Current,,
13631,Azacitidine Injection,"Fresenius Kabi USA, LLC","Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)",Reverified,9/2/25,Available,Check wholesaler inventory,,,Oncology,Current,,
13632,Azacitidine Injection,"Hikma Pharmaceuticals USA, Inc.","Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)",Reverified,7/23/25,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Oncology,Current,,
13633,Azacitidine Injection,"Dr. Reddy's Laboratories, Inc.","Azacitidine, Injection, 100 mg (NDC 43598-305-62)",Reverified,8/15/25,Available,Available to existing customers,,,Oncology,Current,,
13634,Azacitidine Injection,Armas Pharmaceuticals Inc,"Azacitidine, Injection, 100 mg (NDC 72485-201-01)",Reverified,8/19/25,Available,,,,Oncology,Current,,
13635,Azacitidine Injection,Accord Healthcare Inc.,"Azacitidine, Injection, 100 mg (NDC 16729-306-10)",Revised,8/19/25,Limited Availability,TBD,,Regulatory delay,Oncology,Current,,
13636,Azacitidine Injection,"Teva Pharmaceuticals USA, Inc.","Azacitidine, Injection, 100 mg (NDC 68001-313-56)",Revised,8/19/25,Unavailable,Estimated recovery: TBD,,Other,Oncology,Current,,
13637,Azelaic Acid Gel,Leo Pharma Inc.,"Finacea, Gel, .15 g/1 g (NDC 50222-505-50)",New,1/13/25,,,,,Dermatology,To Be Discontinued,,1/13/25
13638,Azelastine Hydrochloride; Fluticasone Propionate Nasal Spray,"Mylan Pharmaceuticals Inc., a Viatris Company","Dymista, Nasal Spray, 137 ug; 50 ug (NDC 0378-3458-23)",New,9/4/25,,Discontinuation of the manufacture of the drug,,,Pulmonary/Allergy,To Be Discontinued,,9/4/25
13639,Azithromycin for Suspension,Pfizer Inc.,"Zithromax, for Suspension, 100 mg/5 mL (NDC 59762-3110-1)",New,10/15/24,,,,,Anti-Infective,To Be Discontinued,,10/15/24
13640,Bacitracin Ophthalmic Ointment,Padagis US LLC,"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)",Revised,7/2/25,Unavailable,Shortage is estimated for 18 months,,Discontinuation of the manufacture of the drug,Anti-Infective; Ophthalmology,Current,,
13641,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 0832-1054-10)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25
13642,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 0832-1054-11)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25
13643,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 0832-1054-15)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25
13644,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 0832-1054-90)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25
13645,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 20 mg (NDC 0832-1055-10)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25
13646,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 20 mg (NDC 0832-1055-11)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25
13647,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 20 mg (NDC 0832-1055-15)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25
13648,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 20 mg (NDC 0832-1055-90)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25
13649,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 50090-6868-0)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25
13650,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 50090-6868-1)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25
13651,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 50090-6868-3)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25
13652,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 50090-6869-0)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25
13653,Benazepril Hydrochloride Tablet,Aurobindo Pharma USA,"Benazepril Hydrochloride, Tablet, 10 mg (NDC 65862-116-01)",New,2/7/25,,,,,Cardiovascular,To Be Discontinued,,2/7/25
13654,Benazepril Hydrochloride Tablet,Aurobindo Pharma USA,"Benazepril Hydrochloride, Tablet, 20 mg (NDC 65862-117-01)",New,2/7/25,,,,,Cardiovascular,To Be Discontinued,,2/7/25
13655,Benazepril Hydrochloride Tablet,Aurobindo Pharma USA,"Benazepril Hydrochloride, Tablet, 40 mg (NDC 65862-118-01)",New,2/7/25,,,,,Cardiovascular,To Be Discontinued,,2/7/25
13656,Bendamustine Hydrochloride Injection,Apotex Corp.,"Bendamustine Hydrochloride, Injection, 25 mg (NDC 60505-6095-0)",New,1/27/25,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,1/27/25
13657,Bendamustine Hydrochloride Injection,Apotex Corp.,"Bendamustine Hydrochloride, Injection, 100 mg (NDC 60505-6096-0)",New,1/27/25,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,1/27/25
13658,Bezlotoxumab Injection,Merck Sharp & Dohme LLC,"Zinplava, Injection, 25 mg/1 mL (NDC 0006-3025-00)",New,12/23/24,,"To be discontinued on January 31, 2025",,,Anti-Infective,To Be Discontinued,,12/23/24
13659,Bleomycin Sulfate Injection,"Hospira, Inc., a Pfizer Company","Bleomycin Sulfate, Injection, 30 [USP'U] (NDC 0409-0323-20)",New,6/13/25,,Discontinuation of the manufacture of the drug,,,Hematology; Oncology; Pediatric,To Be Discontinued,,6/13/25
13660,Bleomycin Sulfate Injection,"Hospira, Inc., a Pfizer Company","Bleomycin Sulfate, Injection, 15 [USP'U] (NDC 0409-0332-20)",New,6/13/25,,Discontinuation of the manufacture of the drug,,,Hematology; Oncology; Pediatric,To Be Discontinued,,6/13/25
13661,Bosentan Tablet,Actelion Pharmaceuticals,"Tracleer, Tablet, 62.5 mg (NDC 66215-101-03)",New,6/9/25,,,,,Cardiovascular,To Be Discontinued,,6/9/25
13662,Bosentan Tablet,Actelion Pharmaceuticals,"Tracleer, Tablet, 125 mg (NDC 66215-102-03)",New,6/9/25,,,,,Cardiovascular,To Be Discontinued,,6/9/25
13663,Brexanolone Solution,"Sage Therapeutics, Inc.","Zulresso, Solution, 5 mg/1 mL (NDC 72152-547-20)",New,10/29/24,,,,,Psychiatry,To Be Discontinued,,10/29/24
13664,Bumetanide Injection,Sagent Pharmaceuticals,"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)",New,8/25/25,Available,,,,Cardiovascular,Current,,
13665,Bumetanide Injection,Sagent Pharmaceuticals,"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)",New,8/25/25,Available,,,,Cardiovascular,Current,,
13666,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc.","Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)",Reverified,7/23/25,Available,,,,Cardiovascular,Current,,
13667,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc.","Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)",Reverified,7/23/25,Available,,,,Cardiovascular,Current,,
13668,Bumetanide Injection,"Fresenius Kabi USA, LLC","Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,
13669,Bumetanide Injection,"Fresenius Kabi USA, LLC","Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,
13670,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)",Revised,8/8/25,Available,,,,Cardiovascular,Current,,
13671,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, .25 mg/1 mL (NDC 72205-101-07)",Revised,8/8/25,Available,,,,Cardiovascular,Current,,
13672,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)",Revised,8/8/25,Available,,,,Cardiovascular,Current,,
13673,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, .25 mg/1 mL (NDC 72205-102-07)",Revised,8/8/25,Available,,,,Cardiovascular,Current,,
13674,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, .5 mg (NDC 0832-0540-11)",New,5/2/25,,,,,Cardiovascular,To Be Discontinued,,5/2/25
13675,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, 1 mg (NDC 0832-0541-10)",New,5/2/25,,,,,Cardiovascular,To Be Discontinued,,5/2/25
13676,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, 1 mg (NDC 0832-0541-11)",New,5/2/25,,,,,Cardiovascular,To Be Discontinued,,5/2/25
13677,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, 2 mg (NDC 0832-0542-10)",New,5/2/25,,,,,Cardiovascular,To Be Discontinued,,5/2/25
13678,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, 2 mg (NDC 0832-0542-11)",New,5/2/25,,,,,Cardiovascular,To Be Discontinued,,5/2/25
13679,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL); 30 mL Single Dose Glass Teartop Vial NOVAPLUS (NDC 0409-1159-10)",New,1/10/25,,Discontinuation of the manufacture of the drug,,,Anesthesia,To Be Discontinued,,1/10/25
13680,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 0409-1610-50)",New,1/10/25,,"Discontinuation of the manufacture of the drug.
Replaced with NDC 0409-0525-01",,,Anesthesia,To Be Discontinued,,1/10/25
13681,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)",Reverified,8/19/25,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,
13682,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)",Reverified,8/19/25,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,
13683,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: December 2028,,Other,Anesthesia,Current,,
13684,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,
13685,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,,
13686,Bupivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,
13687,Bupivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,
13688,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)",Reverified,8/19/25,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,
13689,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)",Reverified,8/19/25,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,
13690,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)",Reverified,8/19/25,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,
13691,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13692,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13693,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13694,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13695,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)",Reverified,9/2/25,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia,Current,,
13696,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13697,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13698,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)",Reverified,9/2/25,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,
13699,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13700,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13701,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13702,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13703,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13704,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13705,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13706,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,
13707,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,
13708,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,
13709,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13710,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13711,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13712,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13713,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)",Revised,8/15/25,Limited Available,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Anesthesia,Current,,
13714,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13715,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13716,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13717,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13718,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2025,,Demand increase for the drug,Anesthesia,Current,,
13719,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13720,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1587-50)",Revised,8/15/25,Unavailable,Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,
13721,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13722,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,
13723,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 250 mg/50 mL (5 mg/mL) (NDC 0409-1610-50)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13724,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 75 mg/10 mL (7.5 mg/mL) (NDC 0409-1582-10)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,
13725,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1582-29)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13726,Bupivacaine Hydrochloride Injection,"Huons Co., Ltd","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,
13727,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,
13728,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,
13729,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,12/19/24,
13730,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,
13731,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,
13732,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,
13733,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13734,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Anesthesia,Current,,
13735,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13736,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13737,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13738,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13739,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)",Reverified,9/2/25,Available,Check wholesaler for inventory,,,Anesthesia,Current,,
13740,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)",Reverified,9/2/25,Available,Check wholesaler for inventory,,,Anesthesia,Current,,
13741,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13742,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13743,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13744,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13745,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)",Reverified,9/2/25,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,
13746,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)",Reverified,9/2/25,Available,8 mos expiry available upon request. Check wholesaler for inventory.,,,Anesthesia,Current,,
13747,Candesartan Cilexetil Tablet,"Par Pharmaceutical, Inc.","Atacand, Tablet, 4 mg (NDC 49884-658-09)",New,10/15/24,,,,,Cardiovascular,To Be Discontinued,,10/15/24
13748,Candesartan Cilexetil Tablet,"Par Pharmaceutical, Inc.","Atacand, Tablet, 8 mg (NDC 49884-659-09)",New,10/15/24,,,,,Cardiovascular,To Be Discontinued,,10/15/24
13749,Candesartan Cilexetil Tablet,"Par Pharmaceutical, Inc.","Atacand, Tablet, 16 mg (NDC 49884-660-09)",New,10/15/24,,,,,Cardiovascular,To Be Discontinued,,10/15/24
13750,Candesartan Cilexetil Tablet,"Par Pharmaceutical, Inc.","Atacand, Tablet, 32 mg (NDC 49884-661-09)",New,10/15/24,,,,,Cardiovascular,To Be Discontinued,,10/15/24
13751,Carbamazepine Tablet,"Teva Pharmaceuticals USA, Inc.","Epitol, Tablet, 200 mg (NDC 0093-0090-01)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/10/25
13752,Carbamazepine Tablet,"Teva Pharmaceuticals USA, Inc.","Epitol, Tablet, 200 mg (NDC 0093-0109-01)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/10/25
13753,Carbamazepine Tablet,"Teva Pharmaceuticals USA, Inc.","Epitol, Tablet, 200 mg (NDC 0093-0109-10)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/10/25
13754,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 10 mg/1 mL (NDC 60505-6282-3)",New,3/28/25,,Discontinuation due to low sales volume. Supply currently available with November 2025 expiry dating. Wholesaler & Distributor through Marketing partner (Apotex Inc.),,,Oncology,To Be Discontinued,,3/28/25
13755,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 10 mg/1 mL (NDC 60505-6282-1)",New,3/28/25,,Discontinuation due to low sales volume. Supply currently available with June 2025 expiry dating. Wholesaler & Distributor through Marketing partner (Apotex Inc.),,,Oncology,To Be Discontinued,,3/28/25
13756,Carboplatin Injection,Accord Healthcare Inc.,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)",Reverified,8/19/25,Unavailable,Pending discontinuation of the manufacture of the drug,,Requirements related to complying with good manufacturing practices,Oncology,Current,,
13757,Carboplatin Injection,Accord Healthcare Inc.,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)",Reverified,8/19/25,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Oncology,Current,,
13758,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)",Reverified,7/24/25,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Oncology,Current,,
13759,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)",Reverified,7/24/25,Limited Availability,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Oncology,Current,,
13760,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)",Reverified,7/24/25,Available,Wholesaler & Distributor through Marketing partner (Apotex Inc.),,,Oncology,Current,,
13761,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)",Reverified,7/24/25,Available,Wholesaler & Distributor through Marketing partner (Apotex Inc.),,,Oncology,Current,,
13762,Carboplatin Injection,Ingenus Pharmaceuticals LLC,"Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45)",Reverified,9/2/25,Unavailable,"For any other information, please contact the Ingenus Customer Service team at 866-321-5031.",,Other,Oncology,Current,,
13763,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)",Revised,7/28/25,Unavailable,"Discontinued; Distributed by BPI Labs, LLC",,Discontinuation of the manufacture of the drug,Oncology,Current,,
13764,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)",Revised,7/28/25,Limited Availability,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",,Demand increase for the drug,Oncology,Current,,
13765,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)",Revised,7/28/25,Limited Availability,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",,Demand increase for the drug,Oncology,Current,,
13766,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)",Revised,7/28/25,Limited Availability,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",,Demand increase for the drug,Oncology,Current,,
13767,Carboplatin Injection,Ingenus Pharmaceuticals LLC,"Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60)",Reverified,9/2/25,Unavailable,"For any other information, please contact the Ingenus Customer Service team at 866-321-5031.",,Other,Oncology,Current,,
13768,Carboplatin Injection,Eugia US LLC,"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Oncology,Current,,
13769,Carboplatin Injection,Eugia US LLC,"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Oncology,Current,,
13770,Carboplatin Injection,Accord Healthcare Inc.,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)",Revised,8/19/25,Limited Availability,Estimated recovery: TBD,,Requirements related to complying with good manufacturing practices,Oncology,Current,,
13771,Carboplatin Injection,Accord Healthcare Inc.,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)",Reverified,8/19/25,Available,,,,Oncology,Current,,
13772,Carboplatin Injection,"Fresenius Kabi USA, LLC","Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Oncology,Current,,
13773,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)",Revised,8/19/25,Limited Availability,,,Delay in shipping of the drug,Oncology,Current,,
13774,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)",Reverified,8/15/25,Available,,,,Oncology,Current,,
13775,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)",Reverified,8/15/25,Available,,,,Oncology,Current,,
13776,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)",Reverified,8/15/25,Available,,,,Oncology,Current,,
13777,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)",Reverified,8/15/25,Available,,,,Oncology,Current,,
13778,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)",Reverified,8/15/25,Available,,,,Oncology,Current,,
13779,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)",Reverified,8/15/25,Available,,,,Oncology,Current,,
13780,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)",Reverified,8/15/25,Available,,,,Oncology,Current,,
13781,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)",Reverified,8/15/25,Available,,,,Oncology,Current,,
13782,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)",Revised,8/19/25,Available,,,,Oncology,Current,,
13783,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)",Revised,8/19/25,Available,,,,Oncology,Current,,
13784,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)",Revised,8/19/25,Limited Availability,Estimated recovery: September 2025,,Other,Oncology,Current,,
13785,Caspofungin Acetate Injection,Merck Sharp & Dohme Corp.,"Cancidas, Injection, 5 mg/1 mL (NDC 0006-3822-10)",New,9/26/24,,"To be discontinued on October 31, 2024",,,Anti-Infective,To Be Discontinued,,9/26/24
13786,"Cefotaxime Sodium Powder, for Solution","SteriMax, Inc.","Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)",Reverified,8/19/25,Available,,,,Anti-Infective; Pediatric,Current,,
13787,"Cefotaxime Sodium Powder, for Solution","SteriMax, Inc.","Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)",Reverified,8/19/25,Available,,,,Anti-Infective; Pediatric,Current,,
13788,"Cefotaxime Sodium Powder, for Solution","Hikma Pharmaceuticals USA, Inc.","Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)",Reverified,7/23/25,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,
13789,"Cefotaxime Sodium Powder, for Solution","Hikma Pharmaceuticals USA, Inc.","Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)",Reverified,7/23/25,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,
13790,"Cefotaxime Sodium Powder, for Solution","Hikma Pharmaceuticals USA, Inc.","Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)",Reverified,7/23/25,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,
13791,"Cefotaxime Sodium Powder, for Solution","Hikma Pharmaceuticals USA, Inc.","Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)",Reverified,7/23/25,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,
13792,Celecoxib Capsule,Apotex Corp.,"Capsule, 50 mg (NDC 60505-3847-6)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24
13793,Celecoxib Capsule,Apotex Corp.,"Capsule, 100 mg (NDC 60505-3848-1)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24
13794,Celecoxib Capsule,Apotex Corp.,"Capsule, 100 mg (NDC 60505-3848-5)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24
13795,Celecoxib Capsule,Apotex Corp.,"Capsule, 200 mg (NDC 60505-3849-1)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24
13796,Celecoxib Capsule,Apotex Corp.,"Capsule, 200 mg (NDC 60505-3849-5)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24
13797,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 50 mg (NDC 0591-3982-60)",New,8/15/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/25
13798,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 100 mg (NDC 0591-3983-01)",New,8/15/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/25
13799,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 100 mg (NDC 0591-3983-05)",New,8/15/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/25
13800,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 200 mg (NDC 0591-3984-01)",New,8/15/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/25
13801,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 200 mg (NDC 0591-3984-05)",New,8/15/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/25
13802,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 400 mg (NDC 0591-3985-60)",New,8/15/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/25
13803,Cholestyramine Powder,"Upsher-Smith Laboratories, LLC","Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-23)",New,5/14/25,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/25
13804,Cholestyramine Powder,"Upsher-Smith Laboratories, LLC","Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-42)",New,5/14/25,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/25
13805,Cholestyramine Powder,"Upsher-Smith Laboratories, LLC","Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-60)",New,5/14/25,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/25
13806,Cisatracurium Besylate Injection,"Teva Pharmaceuticals USA, Inc.","CISATRACURIUM BESYLATE PRESERVATIVE FREE, Injection, 10 mg/5 mL (NDC 0703-2033-03)",New,1/6/25,,,,,Anesthesia,To Be Discontinued,,1/6/25
13807,Cisatracurium Besylate Injection,"Teva Pharmaceuticals USA, Inc.","CISATRACURIUM BESYLATE PRESERVATIVE FREE, Injection, 200 mg/20 mL (NDC 0703-2045-03)",New,1/6/25,,,,,Anesthesia,To Be Discontinued,,1/6/25
13808,Cisatracurium Besylate Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 20 mg/10 mL (NDC 0703-2056-03)",New,1/6/25,,,,,Anesthesia,To Be Discontinued,,1/6/25
13809,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-01)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24
13810,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-03)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24
13811,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-05)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24
13812,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-77)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24
13813,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-01)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24
13814,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-03)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24
13815,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-05)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24
13816,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-11)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24
13817,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-16)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24
13818,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-62)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24
13819,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-77)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24
13820,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)",Revised,8/15/25,Unavailable,Next Delivery and Estimated Recovery: December 2025,,Other,Anti-Infective,Current,,
13821,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: April 2026; Estimated Recovery: June 2026,,Other,Anti-Infective,Current,,
13822,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)",Revised,8/15/25,Available,,,,Anti-Infective,Current,,
13823,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)",Revised,8/15/25,Available,,,,Anti-Infective,Current,,
13824,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)",Revised,8/15/25,Unavailable,Next Delivery and Estimated Recovery: December 2025,,Other,Anti-Infective,Current,,
13825,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 9 g/60 mL (150 mg/mL) (NDC 0009-0728-09)",Revised,8/15/25,Unavailable,Next Delivery: February 2026; Estimated Recovery: March 2026,,Demand increase for the drug,Anti-Infective,Current,,
13826,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2025,,Other,Anti-Infective,Current,,
13827,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)",Reverified,8/26/25,Available,,,,Anti-Infective,Current,,
13828,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)",Reverified,8/26/25,Available,,,,Anti-Infective,Current,,
13829,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)",Reverified,8/26/25,Available,,,,Anti-Infective,Current,,
13830,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)",Reverified,8/15/25,Unavailable,Estimated recovery: September 2025,,Demand increase for the drug,Anti-Infective,Current,,
13831,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)",Revised,8/15/25,Limited Availability,Estimated recovery: October 2025,,Other,Anti-Infective,Current,,
13832,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)",Reverified,8/15/25,Available,,,,Anti-Infective,Current,,
13833,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)",Reverified,9/3/25,Unavailable,Estimated recovery: September 2025,,Demand increase for the drug,Anti-Infective,Current,,
13834,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)",Reverified,9/3/25,Available,,,,Anti-Infective,Current,,
13835,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)",Revised,8/15/25,Unavailable,Estimated recovery: November 2025,,Demand increase for the drug,Anti-Infective,Current,,
13836,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)",Reverified,8/15/25,Available,,,,Anti-Infective,Current,,
13837,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)",Reverified,8/15/25,Available,,,,Anti-Infective,Current,,
13838,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)",Reverified,8/15/25,Available,,,,Anti-Infective,Current,,
13839,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)",Reverified,8/15/25,Available,Civica Label,,,Anti-Infective,Current,,
13840,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)",Reverified,8/15/25,Available,Civica Label,,,Anti-Infective,Current,,
13841,Clindamycin Phosphate; Benzoyl Peroxide Gel,"Teva Pharmaceuticals USA, Inc.","Clindamycin Phosphate; Benzoyl Peroxide, Gel, 25 mg/1 g; 10 mg/1 g (NDC 0591-3916-68)",New,8/1/25,,A business decision was made to discontinue manufacture of the product.,,,Dermatology,To Be Discontinued,,8/1/25
13842,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-00)",Reverified,8/19/25,Information pending,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,
13843,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-00)",Reverified,8/19/25,Information pending,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,
13844,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, .5 mg (NDC 59651-722-01)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13845,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, .5 mg (NDC 59651-722-99)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13846,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, 1 mg (NDC 59651-723-01)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13847,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, 1 mg (NDC 59651-723-99)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13848,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, 2 mg (NDC 59651-724-01)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13849,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, 2 mg (NDC 59651-724-05)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13850,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, .5 mg (NDC 16729-136-00)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13851,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, .5 mg (NDC 16729-136-16)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13852,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, 1 mg (NDC 16729-137-00)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13853,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, 1 mg (NDC 16729-137-16)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13854,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, 2 mg (NDC 16729-138-00)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13855,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, 2 mg (NDC 16729-138-16)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13856,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, .5 mg (NDC 61269-605-10)",Reverified,9/3/25,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,
13857,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, 1 mg (NDC 61269-610-10)",Reverified,9/3/25,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,
13858,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, 2 mg (NDC 61269-620-10)",Reverified,9/3/25,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,
13859,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-10)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,
13860,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-11)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,
13861,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-50)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,
13862,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-10)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,
13863,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-11)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,
13864,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-50)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,
13865,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 2 mg (NDC 43547-408-10)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,
13866,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 2 mg (NDC 43547-408-50)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,
13867,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13868,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13869,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13870,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13871,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)",Reverified,8/19/25,Limited Availability,Estimated recovery: September 2025,,Other,Neurology; Pediatric; Psychiatry,Current,,
13872,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,
13873,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,
13874,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,
13875,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,
13876,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,
13877,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,
13878,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,
13879,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,
13880,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,
13881,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,
13882,Conivaptan Hydrochloride Injection,Cumberland Pharmaceuticals Inc.,"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)",Reverified,8/15/25,Unavailable,,,Delay in shipping of the drug,Cardiovascular,Current,,
13883,Cromolyn Sodium Concentrate,"Rising Pharma Holdings, Inc.","Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)",Revised,8/15/25,Available,,,,Pulmonary/Allergy,Current,,
13884,Cromolyn Sodium Concentrate,Micro Labs LTD,"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)",Reverified,9/2/25,Available,,,,Pulmonary/Allergy,Current,,
13885,Cromolyn Sodium Concentrate,"Mylan Specialty, a Viatris Company","Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)",Reverified,9/3/25,Available,,,,Pulmonary/Allergy,Current,,
13886,Cromolyn Sodium Concentrate,Ailex Pharmaceuticals,"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)",Revised,8/15/25,Available,Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195,,,Pulmonary/Allergy,Current,,
13887,Cyanocobalamin Injection,Accord Healthcare Inc.,"Dodex, Injection, 1000 ug/1 mL (NDC 16729-533-08)",New,1/17/25,,Permanent discontinuation in the manufacturing of the drug.,,,Hematology,To Be Discontinued,,1/17/25
13888,Cyclosporine Oral Solution,AbbVie Inc.,"Gengraf, Oral Solution, 100 mg/ml (NDC 0074-7269-50)",New,12/5/24,,"Abbvie has made a business decision to permanently discontinue GENGRAF Oral Solution (cyclosporine oral solution, USP) 100 mg/mL .",,,Transplant,To Be Discontinued,,12/5/24
13889,"Dalfampridine Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Tablet, Extended Release, 10 mg (NDC 62756-429-86)",New,9/20/24,,,,,Neurology,To Be Discontinued,,9/20/24
13890,Dapagliflozin; Saxaglipitin Hydrochloride Tablet,AstraZeneca AB,"Qtern, Tablet, 5 mg; 5 mg (NDC 0310-6770-30)",New,3/3/25,,,,,Endocrinology/Metabolism,To Be Discontinued,,
13891,Dapagliflozin; Saxaglipitin Hydrochloride Tablet,AstraZeneca AB,"Qtern, Tablet, 10 mg; 5 mg (NDC 0310-6780-30)",New,3/3/25,,,,,Endocrinology/Metabolism,To Be Discontinued,,3/3/25
13892,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 1 mg (NDC 0173-0897-13)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24
13893,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 1 mg (NDC 0173-0897-56)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24
13894,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 2 mg (NDC 0173-0903-13)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24
13895,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 2 mg (NDC 0173-0903-56)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24
13896,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 4 mg (NDC 0173-0906-13)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24
13897,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 4 mg (NDC 0173-0906-56)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24
13898,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 6 mg (NDC 0173-0911-13)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24
13899,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 6 mg (NDC 0173-0911-56)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24
13900,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 8 mg (NDC 0173-0914-13)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24
13901,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 8 mg (NDC 0173-0914-56)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24
13902,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 10 mg (NDC 23155-578-01)",New,8/12/25,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/25
13903,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 25 mg (NDC 23155-579-01)",New,8/12/25,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/25
13904,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 50 mg (NDC 23155-580-01)",New,8/12/25,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/25
13905,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 75 mg (NDC 23155-581-01)",New,8/12/25,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/25
13906,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 100 mg (NDC 23155-582-01)",New,8/12/25,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/25
13907,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 150 mg (NDC 23155-583-25)",New,8/12/25,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/25
13908,Desmopressin Acetate Injection,Sun Pharmaceutical Industries Limited,"Desmopressin Acetate, Injection, 4 ug/1 mL (NDC 62756-529-40)",New,12/5/24,,Discontinuing for business reasons,,,Endocrinology/Metabolism,To Be Discontinued,,12/5/24
13909,Desmopressin Acetate Spray,Ferring,"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)",Reverified,6/27/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,
13910,Desmopressin Acetate Spray,Ferring,"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)",Reverified,6/27/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,
13911,Desmopressin Acetate Spray,Apotex Corp.,"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)",Reverified,7/24/25,Available,,,,Hematology,Current,,
13912,Desmopressin Acetate Spray,Ferring,"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)",Reverified,6/27/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,
13913,Desonide Cream,"Actavis Pharma, Inc.","Desowen, Cream, .5 mg/1 g (NDC 0472-0804-15)",New,5/28/25,,,,,Dermatology,To Be Discontinued,,5/28/25
13914,Desonide Cream,"Actavis Pharma, Inc.","Desowen, Cream, .5 mg/1 g (NDC 0472-0804-60)",New,5/28/25,,,,,Dermatology,To Be Discontinued,,5/28/25
13915,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-106-10)",Reverified,9/2/25,Unavailable,Not available at this time.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13916,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-109-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13917,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13918,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 100 mg/10 mL (NDC 55150-305-10)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13919,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)",Reverified,9/3/25,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13920,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)",Reverified,9/3/25,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13921,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)",Reverified,9/3/25,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13922,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)",Reverified,9/3/25,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13923,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-237-01)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13924,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-238-05)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13925,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-239-30)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13926,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, LLC","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)",Reverified,8/19/25,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13927,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)",Reverified,9/2/25,Available,Check wholesalers for inventory.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13928,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13929,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13930,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)",Reverified,9/2/25,Available,Check wholesalers for inventory.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13931,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13932,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)",Revised,7/23/25,Available,Currently available.  Additional product will be made available as it is released.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13933,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)",Reverified,7/23/25,Unavailable,Additional lots will be available in the April 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13934,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)",Reverified,7/23/25,Available,Currently available.  Additional product will be made available as it is released.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,
13935,Dexmedetomidine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)",Reverified,7/23/25,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anesthesia,Current,,
13936,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)",Reverified,9/2/25,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,
13937,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)",Reverified,9/2/25,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,
13938,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,
13939,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,
13940,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,
13941,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,
13942,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)",Reverified,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13943,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)",Reverified,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13944,Dexmedetomidine Hydrochloride Injection,Accord Healthcare Inc.,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)",Reverified,8/19/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Anesthesia,Current,,
13945,Dexmedetomidine Hydrochloride Injection,Accord Healthcare Inc.,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)",Reverified,8/19/25,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia,Current,,
13946,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)",Reverified,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
13947,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,
13948,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)",Revised,9/3/25,Limited Availability,Recovery in November 2025,,Demand increase for the drug,Anesthesia,Current,,
13949,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,
13950,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,
13951,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)",Reverified,9/2/25,Unavailable,Not available at this time.,,Other,Anesthesia,Current,,
13952,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)",Reverified,9/2/25,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,
13953,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)",Reverified,9/2/25,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,
13954,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)",Reverified,9/2/25,Available,Short-dated supply (8 months from expiry) available upon request. Check wholesaler for inventory.,,,Anesthesia,Current,,
13955,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)",Reverified,7/16/25,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,
13956,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)",Reverified,7/16/25,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,
13957,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)",Reverified,7/16/25,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,
13958,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)",Reverified,7/16/25,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,
13959,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,
13960,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)",Reverified,9/2/25,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,
13961,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13962,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13963,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13964,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13965,Dexmedetomidine Hydrochloride Injection,Slayback Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-05)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,
13966,Dexmedetomidine Hydrochloride Injection,Slayback Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-06)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,
13967,Dexmedetomidine Hydrochloride Injection,"Meitheal Pharmaceuticals, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,
13968,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)",Reverified,7/28/25,Available,Distributed by DRL,,,Anesthesia,Current,,
13969,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)",Reverified,7/28/25,Available,Distributed by DRL,,,Anesthesia,Current,,
13970,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,
13971,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,
13972,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL  (NDC 0781-3493-95)",Reverified,9/2/25,Available,Marketed by Sandoz Inc.; Customer service: 800-525-8747,,,Anesthesia,Current,,
13973,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL  (NDC 0781-3494-95)",Reverified,9/2/25,Available,Marketed by Sandoz Inc.; Customer service: 800-525-8747,,,Anesthesia,Current,,
13974,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)",Reverified,9/2/25,Available,Marketed by Sandoz Inc.; Customer service: 800-525-8747,,,Anesthesia,Current,,
13975,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)",Reverified,7/28/25,Available,Marketed by Piramal Critical Care Inc.: 800-414-1901,,,Anesthesia,Current,,
13976,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13977,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13978,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13979,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13980,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)",Revised,8/15/25,Unavailable,Unavailable. Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,
13981,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: November 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,
13982,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
13983,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)",Reverified,9/2/25,Unavailable,Distributed by Avenacy; Contact information: 877-283-6229,,Demand increase for the drug,Anesthesia,Current,,
13984,Dextrose Monohydrate 10% Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13985,Dextrose Monohydrate 10% Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13986,Dextrose Monohydrate 10% Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13987,Dextrose Monohydrate 10% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13988,Dextrose Monohydrate 10% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13989,Dextrose Monohydrate 10% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13990,Dextrose Monohydrate 10% Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13991,Dextrose Monohydrate 10% Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesalers for inventory.,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13992,Dextrose Monohydrate 10% Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13993,Dextrose Monohydrate 10% Injection,Otsuka ICU Medical LLC,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13994,Dextrose Monohydrate 10% Injection,Otsuka ICU Medical LLC,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13995,Dextrose Monohydrate 10% Injection,Otsuka ICU Medical LLC,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13996,Dextrose Monohydrate 10% Injection,Otsuka ICU Medical LLC,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13997,Dextrose Monohydrate 5% Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 2.5 g/50mL (5%, 50mg/mL) (NDC 0409-7100-66)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13998,Dextrose Monohydrate 5% Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 5 g/100mL (5%) Plastic (NDC 0409-7100-67)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
13999,Dextrose Monohydrate 5% Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 12.5 g/250mL (5%) (NDC 0409-7100-02)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14000,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14001,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14002,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14003,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14004,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)",Reverified,9/2/25,Available,Check wholealers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14005,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14006,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14007,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14008,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14009,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14010,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14011,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14012,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14013,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14014,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14015,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14016,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14017,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14018,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14019,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14020,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9143-30)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14021,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9147-30)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14022,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14023,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14024,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14025,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0062-30)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14026,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14027,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0066-20)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14028,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14029,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14030,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14031,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)",Revised,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14032,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)",Revised,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14033,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14034,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14035,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14036,Dextrose Monohydrate 50% Injection,"Amphastar Pharmaceuticals, Inc.","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)",Reverified,8/19/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,
14037,Dextrose Monohydrate 50% Injection,"Hospira, Inc., a Pfizer Company","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)",Revised,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,
14038,Dextrose Monohydrate 50% Injection,"Hospira, Inc., a Pfizer Company","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,
14039,Dextrose Monohydrate 50% Injection,"Hospira, Inc., a Pfizer Company","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,
14040,Dextrose Monohydrate 70% Injection,Otsuka ICU Medical LLC,"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14041,Dextrose Monohydrate 70% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14042,Dextrose Monohydrate 70% Injection,Otsuka ICU Medical LLC,"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14043,Dextrose Monohydrate 70% Injection,Baxter Healthcare,"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,
14044,Digoxin Tablet,Sun Pharmaceutical Industries Limited,"Digoxin, Tablet, 125 ug (NDC 57664-437-88)",New,12/5/24,,Discontinuing for business reasons,,,Cardiovascular,To Be Discontinued,,12/5/24
14045,Digoxin Tablet,Sun Pharmaceutical Industries Limited,"Digoxin, Tablet, 125 ug (NDC 57664-437-18)",New,12/5/24,,Discontinuing for business reasons,,,Cardiovascular,To Be Discontinued,,12/5/24
14046,Digoxin Tablet,Sun Pharmaceutical Industries Limited,"Digoxin, Tablet, 250 ug (NDC 57664-441-18)",New,12/5/24,,Discontinuing for business reasons,,,Cardiovascular,To Be Discontinued,,12/5/24
14047,Digoxin Tablet,Sun Pharmaceutical Industries Limited,"Digoxin, Tablet, 250 ug (NDC 57664-441-88)",New,12/5/24,,Discontinuing for business reasons,,,Cardiovascular,To Be Discontinued,,12/5/24
14048,Dihydroergotamine Mesylate Injection,Padagis US LLC,"Injection, 1 mg/1 mL (NDC 0574-0850-05)",New,9/16/24,,,,,Neurology,To Be Discontinued,,9/16/24
14049,Dihydroergotamine Mesylate Injection,Padagis US LLC,"Injection, 1 mg/1 mL (NDC 0574-0850-10)",New,9/16/24,,,,,Neurology,To Be Discontinued,,9/16/24
14050,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 125 mg (NDC 0832-7122-11)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25
14051,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 125 mg (NDC 0832-7122-15)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25
14052,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-01)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25
14053,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-11)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25
14054,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-15)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25
14055,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-01)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25
14056,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-11)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25
14057,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-15)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25
14058,Dobutamine Hydrochloride Injection,Pfizer Inc.,"Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-88)",New,8/27/25,,Discontinuation of the manufacture of the drug,,,Cardiovascular; Pediatric; Renal,To Be Discontinued,,8/27/25
14059,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)",Reverified,9/3/25,Available,,,,Cardiovascular; Pediatric; Renal,Current,,
14060,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)",Reverified,9/3/25,Available,,,,Cardiovascular; Pediatric; Renal,Current,,
14061,Dobutamine Hydrochloride Injection,"Hainan Poly Pharm. Co., Ltd.","Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)",Reverified,9/3/25,Available,"Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988",,,Cardiovascular; Pediatric; Renal,Current,,
14062,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular; Pediatric; Renal,Current,,
14063,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)",Reverified,9/3/25,Available,,,,Cardiovascular; Pediatric; Renal,Current,,
14064,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)",Revised,8/15/25,Unavailable,Next Delivery: November 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,
14065,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)",Revised,8/15/25,Unavailable,Next Delivery: November 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,12/19/24,
14066,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)",Revised,8/15/25,Unavailable,Next Delivery: November 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,12/19/24,
14067,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)",Revised,8/15/25,Available,,,,Cardiovascular; Pediatric; Renal,Current,12/19/24,
14068,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)",Revised,8/15/25,Available,,,,Cardiovascular; Pediatric; Renal,Current,12/19/24,
14069,Docetaxel Injection,Pfizer Inc.,"Docetaxel, Injection, 160 mg/16 mL (10 mg/mL) Multiple Dose ONCO-TAIN‚Äö√Ñ√∂‚àö√´¬¨¬¢ Glass Fliptop Vial Novaplus¬¨¬®‚àö√ú  (NDC 0409-0016-01)",New,6/24/25,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,6/24/25
14070,Docetaxel Injection,Pfizer Inc.,"Docetaxel, Injection, 20 mg/2 mL (10 mg/mL) Single Dose ONCO-TAIN‚Äö√Ñ√∂‚àö√´¬¨¬¢ Glass Fliptop Vial Novaplus¬¨¬®‚àö√ú  (NDC 0409-2026-01)",New,6/24/25,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,6/24/25
14071,Docetaxel Injection,Pfizer Inc.,"Docetaxel, Injection, 10 mg/1 mL (NDC 0409-1732-01)",New,1/15/25,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,1/15/25
14072,Docetaxel Injection,Pfizer Inc.,"Docetaxel, Injection, 10 mg/1 mL (NDC 0409-7870-01)",New,1/15/25,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,1/15/25
14073,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-01)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25
14074,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-03)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25
14075,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-05)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25
14076,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-06)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25
14077,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-01)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25
14078,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-03)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25
14079,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-05)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25
14080,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-06)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25
14081,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride in Dextrose 5% in plastic container, Injection, 800 mg/500 mL (1,600 mcg/mL) (NDC 0409-7809-24)",New,8/27/25,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To Be Discontinued,,
14082,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)",Revised,8/15/25,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Cardiovascular,Current,,
14083,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,
14084,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)",Revised,8/15/25,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Cardiovascular,Current,,
14085,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)",Revised,8/15/25,Available,,,,Cardiovascular,Current,,
14086,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)",Revised,8/15/25,Available,,,,Cardiovascular,Current,,
14087,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,
14088,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)",Revised,7/23/25,Unavailable,Additional lots will be available in the October 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,
14089,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)",Revised,7/23/25,Unavailable,Additional lots will be available in the October 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,
14090,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,
14091,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,
14092,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,
14093,Doxycycline Hyclate Tablet,"Teva Pharmaceuticals USA, Inc.","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-05)",New,5/2/25,,,,,Anti-Infective,To Be Discontinued,,
14094,Doxycycline Hyclate Tablet,"Teva Pharmaceuticals USA, Inc.","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-50)",New,5/2/25,,,,,Anti-Infective,To Be Discontinued,,5/2/25
14095,Doxycycline Hyclate Tablet,"Teva Pharmaceuticals USA, Inc.","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-05)",New,6/13/25,,,,,Anti-Infective,To Be Discontinued,,6/13/25
14096,Doxycycline Hyclate Tablet,"Teva Pharmaceuticals USA, Inc.","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-50)",New,6/13/25,,,,,Anti-Infective,To Be Discontinued,,6/13/25
14097,Drospirenone; Ethinyl Estradiol Tablet,"Teva Pharmaceuticals USA, Inc.","Yasmin, Tablet, Kit (NDC 0555-9131-67)",New,6/13/25,,,,,Reproductive,To Be Discontinued,,6/13/25
14098,Drospirenone; Ethinyl Estradiol Tablet,"Teva Pharmaceuticals USA, Inc.","Ocella, Tablet, Kit (NDC 0555-9131-67)",New,5/2/25,,,,,Reproductive,To Be Discontinued,,5/2/25
14099,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, .75 mg/.5 mL (NDC 0002-1433-80)",Revised,6/13/25,,,Available,,Endocrinology/Metabolism,Resolved,6/13/25,
14100,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 1.5 mg/.5 mL (NDC 0002-1434-80)",Revised,6/13/25,,,Available,,Endocrinology/Metabolism,Resolved,6/13/25,
14101,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 3 mg/.5 mL (NDC 0002-2236-80)",Revised,6/13/25,,,Available,,Endocrinology/Metabolism,Resolved,6/13/25,
14102,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 4.5 mg/.5 mL (NDC 0002-3182-80)",Revised,6/13/25,,,Available,,Endocrinology/Metabolism,Resolved,6/13/25,
14103,"Duloxetine Hydrochloride Capsule, Delayed Release",Eli Lilly and Co.,"Cymbalta, Capsule, Delayed Release, 20 mg (NDC 0002-3235-60)",New,10/18/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/18/24
14104,"Duloxetine Hydrochloride Capsule, Delayed Release",Eli Lilly and Co.,"Cymbalta, Capsule, Delayed Release, 30 mg (NDC 0002-3240-30)",New,10/18/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/18/24
14105,"Duloxetine Hydrochloride Capsule, Delayed Release",Eli Lilly and Co.,"Cymbalta, Capsule, Delayed Release, 30 mg (NDC 0002-3240-90)",New,10/18/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/18/24
14106,"Duloxetine Hydrochloride Capsule, Delayed Release",Eli Lilly and Co.,"Cymbalta, Capsule, Delayed Release, 60 mg (NDC 0002-3270-30)",New,10/18/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/18/24
14107,Echothiophate Iodide Ophthalmic Solution,Fera Pharmaceuticals,"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)",Reverified,6/27/25,Available,Available through limited distribution by Walgreens Specialty Pharmacy.,,,Ophthalmology,Current,,
14108,Edaravone Injection,"Mitsubishi Tanabe Pharma America, Inc.","Radicava, Injection, 30 mg/100 mL (NDC 70510-2171-2)",New,12/5/24,,"A business decision was made to discontinue manufacture of this product. Distribution will end as early as April 1, 2025. The discontinuation of Radicava (edaravone) injection will not impact the commercial availability of Radicava ORS (edaravone) oral suspension.",,,Neurology,To Be Discontinued,,12/5/24
14109,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14110,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)",Reverified,9/2/25,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,
14111,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14112,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14113,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,12/19/24,
14114,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14115,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14116,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,12/19/24,
14117,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14118,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14119,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14120,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,12/19/24,
14121,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14122,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14123,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14124,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14125,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14126,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)",Reverified,9/2/25,Available,8 mos expiry available upon request. Check wholesaler for inventory.,,,Anesthesia; Pediatric,Current,,
14127,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14128,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14129,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)",Reverified,9/2/25,Available,8 mos expiry available upon request. Check wholesaler for inventory.,,,Anesthesia; Pediatric,Current,,
14130,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14131,Epoprostenol Sodium Injection,GlaxoSmithKline,"Flolan, Injection, .5 mg (NDC 0173-0517-00)",New,1/31/25,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",,,Cardiovascular,To Be Discontinued,,1/31/25
14132,Epoprostenol Sodium Injection,GlaxoSmithKline,"Flolan, Injection, 1.5 mg (NDC 0173-0519-00)",New,1/31/25,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",,,Cardiovascular,To Be Discontinued,,1/31/25
14133,Epoprostenol Sodium Injection,GlaxoSmithKline,"Flolan, Injection, 1 mL/1 mL (NDC 0173-0857-02)",New,1/31/25,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",,,Cardiovascular,To Be Discontinued,,1/31/25
14134,Erythromycin  Topical Gel,"Mylan Pharmaceuticals Inc., a Viatris Company","Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8075-60)",New,2/14/25,,,,,Anti-Infective; Dermatology,To Be Discontinued,,2/14/25
14135,Erythromycin  Topical Gel,"Mylan Pharmaceuticals Inc., a Viatris Company","Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8075-93)",New,2/14/25,,,,,Anti-Infective; Dermatology,To Be Discontinued,,2/14/25
14136,Erythromycin  Topical Gel,"Mylan Pharmaceuticals Inc., a Viatris Company","Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8212-60)",New,2/14/25,,,,,Anti-Infective; Dermatology,To Be Discontinued,,2/14/25
14137,Erythromycin  Topical Gel,"Mylan Pharmaceuticals Inc., a Viatris Company","Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8212-93)",New,2/14/25,,,,,Anti-Infective; Dermatology,To Be Discontinued,,2/14/25
14138,Esterified Estrogens Tablet,Pfizer Inc.,"Menest, Tablet, .3 mg (NDC 61570-072-01)",New,7/29/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/29/25
14139,Esterified Estrogens Tablet,Pfizer Inc.,"Menest, Tablet, .625 mg (NDC 61570-073-01)",New,7/29/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/29/25
14140,Esterified Estrogens Tablet,Pfizer Inc.,"Menest, Tablet, 1.25 mg (NDC 61570-074-01)",New,7/29/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/29/25
14141,Esterified Estrogens Tablet,Pfizer Inc.,"Menest, Tablet, 2.5 mg (NDC 61570-075-50)",New,7/29/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/29/25
14142,Eszopiclone Tablet,"Teva Pharmaceuticals USA, Inc.","Eszopiclone, Tablet, 1 mg (NDC 0093-5537-56)",New,6/26/25,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/26/25
14143,Eszopiclone Tablet,"Teva Pharmaceuticals USA, Inc.","Eszopiclone, Tablet, 2 mg (NDC 0093-5538-01)",New,6/26/25,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/26/25
14144,Eszopiclone Tablet,"Teva Pharmaceuticals USA, Inc.","Eszopiclone, Tablet, 3 mg (NDC 0093-5539-01)",New,6/26/25,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/26/25
14145,Ethinyl Estradiol; Ethinyl Diacetate Tablet,"Teva Pharmaceuticals USA, Inc.","Zovia 1/50E-28, Tablet, Kit (NDC 0093-8073-16)",New,6/13/25,,,,,Reproductive,To Be Discontinued,,6/13/25
14146,Ethinyl Estradiol; Etonogestrel Ring,"Teva Pharmaceuticals USA, Inc.","Ethinyl Estradiol; Etonogestrel, Ring, .015 mg/1 d; .12 mg/1 d (NDC 0093-7679-02)",New,6/16/25,,Discontinuation of the manufacture of the drug,,,Reproductive,To Be Discontinued,,6/16/25
14147,"Ethinyl Estradiol; Norethindrone Tablet, Chewable","Teva Pharmaceuticals USA, Inc.","Tablet, Chewable, Kit (NDC 52544-064-31)",New,1/10/25,,,,,Reproductive,To Be Discontinued,,1/10/25
14148,Ethionamide Tablet,Pfizer Inc.,"Trecator, Tablet, 250 mg (NDC 0008-4117-01)",New,7/16/25,,"Discontinuation of the manufacture of the drug.

Supply expected to exhaust September 2025",,,Anti-Infective,To Be Discontinued,,7/16/25
14149,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 2 mg/1 mL (NDC 65219-445-10)",Reverified,9/2/25,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi,,,Anesthesia,Current,,
14150,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 40 mg/20 mL (NDC 65219-445-20)",Reverified,9/2/25,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi,,,Anesthesia,Current,,
14151,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)",Revised,7/23/25,Available,Distributed by Civica,,,Anesthesia,Current,,
14152,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)",Revised,7/23/25,Available,Distributed by Civica,,,Anesthesia,Current,,
14153,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 2 mg/mL (NDC 65219-447-20)",Reverified,9/2/25,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi 800-551-7176,,,Anesthesia,Current,,
14154,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)",Reverified,9/2/25,Available,"Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586",,,Anesthesia,Current,,
14155,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)",Reverified,9/2/25,Available,"Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586",,,Anesthesia,Current,,
14156,Etomidate Injection,Eugia US LLC,"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)",Reverified,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
14157,Etomidate Injection,Eugia US LLC,"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)",Reverified,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,
14158,Etomidate Injection,Gland Pharma Limited,"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)",Reverified,7/28/25,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Anesthesia,Current,,
14159,Etomidate Injection,Gland Pharma Limited,"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)",Reverified,7/28/25,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Anesthesia,Current,,
14160,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)",Revised,7/23/25,Unavailable,Additional lots will be available in the October 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,
14161,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)",Revised,7/23/25,Available,Currently available.  Additional product will be made available as it is released.,,,Anesthesia,Current,,
14162,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)",Revised,7/23/25,Available,Novaplus,,,Anesthesia,Current,,
14163,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)",Revised,7/23/25,Available,Novaplus,,,Anesthesia,Current,,
14164,Etomidate Injection,"Mylan Institutional, a Viatris Company","Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,
14165,Etomidate Injection,"Mylan Institutional, a Viatris Company","Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,
14166,Etomidate Injection,"Hospira, Inc., a Pfizer Company","Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
14167,Etomidate Injection,"Hospira, Inc., a Pfizer Company","Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)",Revised,8/15/25,Unavailable,Next Delivery: February 2026; Estimated Recovery: March 2026,,Other,Anesthesia,Current,,
14168,"Exenatide Synthetic Injectable Suspension, Extended Release",AstraZeneca AB,"Bydureon BCise, Injectable Suspension, Extended Release, 2 mg/.85 mL (NDC 0310-6540-04)",New,10/28/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,10/28/24
14169,Exenatide Synthetic Injection,AstraZeneca AB,"Byetta, Injection, 300MCG/1.2ML (250MCG/ML) (NDC 0310-6512-01)",New,10/25/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,10/25/24
14170,Exenatide Synthetic Injection,AstraZeneca AB,"Byetta, Injection, 600MCG/2.4ML (250MCG/ML) (NDC 0310-6524-01)",New,10/25/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,10/25/24
14171,Ezetimibe Tablet,"Actavis Pharma, Inc.","Ezetimibe, Tablet, 10 mg (NDC 0591-3713-05)",New,6/27/25,,A business decision was made to discontinue manufacture of the product,,,Cardiovascular,To Be Discontinued,,6/27/25
14172,Ezetimibe Tablet,"Actavis Pharma, Inc.","Ezetimibe, Tablet, 10 mg (NDC 0591-3713-19)",New,6/27/25,,A business decision was made to discontinue manufacture of the product,,,Cardiovascular,To Be Discontinued,,6/27/25
14173,Ezetimibe Tablet,"Actavis Pharma, Inc.","Ezetimibe, Tablet, 10 mg (NDC 0591-3713-30)",New,6/27/25,,A business decision was made to discontinue manufacture of the product,,,Cardiovascular,To Be Discontinued,,6/27/25
14174,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 10 mg (NDC 45963-565-08)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25
14175,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 10 mg (NDC 45963-565-30)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25
14176,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 20 mg (NDC 45963-566-08)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25
14177,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 20 mg (NDC 45963-566-30)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25
14178,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 40 mg (NDC 45963-567-08)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25
14179,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 40 mg (NDC 45963-567-30)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25
14180,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 80 mg (NDC 45963-568-08)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25
14181,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 80 mg (NDC 45963-568-30)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25
14182,Febuxostat Tablet,Takeda Pharmaceuticals USA Inc.,"Uloric, Tablet, 80 mg (NDC 64764-677-30)",New,1/22/25,,Anticipate continued distribution to wholesalers until March 2026,,,Other,To Be Discontinued,,1/22/25
14183,Febuxostat Tablet,Takeda Pharmaceuticals USA Inc.,"Uloric, Tablet, 40 mg (NDC 64764-918-30)",New,1/22/25,,Anticipate continued distribution to wholesalers until March 2026,,,Other,To Be Discontinued,,1/22/25
14184,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesalers for inventory.,,Other,Analgesia/Addiction; Pediatric,Current,,
14185,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)",Reverified,9/2/25,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction; Pediatric,Current,,
14186,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,
14187,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)",Reverified,9/2/25,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction; Pediatric,Current,,
14188,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,
14189,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)",Revised,7/23/25,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,
14190,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,
14191,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)",Reverified,8/15/25,Available,,,,Analgesia/Addiction; Pediatric,Current,,
14192,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)",Reverified,8/15/25,Available,,,,Analgesia/Addiction; Pediatric,Current,,
14193,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)",Reverified,8/15/25,Available,,,,Analgesia/Addiction; Pediatric,Current,1/2/25,
14194,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)",Reverified,8/15/25,Available,,,,Analgesia/Addiction; Pediatric,Current,,
14195,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)",Reverified,8/15/25,Available,,,,Analgesia/Addiction; Pediatric,Current,,
14196,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)",Revised,7/23/25,Unavailable,Inventory available in vial presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,
14197,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)",Revised,7/23/25,Unavailable,Inventory available in vial presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,
14198,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)",Revised,7/23/25,Unavailable,Inventory available in vial presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,
14199,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)",Revised,7/23/25,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,
14200,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)",Revised,7/23/25,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,
14201,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)",Revised,7/23/25,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,
14202,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)",Revised,7/23/25,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,
14203,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 100 ug (NDC 63459-541-28)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24
14204,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 200 ug (NDC 63459-542-28)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24
14205,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 400 ug (NDC 63459-544-28)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24
14206,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 600 ug (NDC 63459-546-28)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24
14207,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 800 ug (NDC 63459-548-28)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24
14208,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 200 ug (NDC 0093-7865-65)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24
14209,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 400 ug (NDC 0093-7866-65)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24
14210,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 600 ug (NDC 0093-7867-65)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24
14211,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 800 ug (NDC 0093-7868-65)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24
14212,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 1200 ug (NDC 0093-7869-65)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24
14213,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 1600 ug (NDC 0093-7870-65)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24
14214,Finasteride Tablet,"Teva Pharmaceuticals USA, Inc.","Finasteride, Tablet, 5 mg (NDC 0093-7355-05)",New,8/19/25,,Discontinuation of the manufacture of the drug product,,,Urology,To Be Discontinued,,8/19/25
14215,Finasteride Tablet,"Teva Pharmaceuticals USA, Inc.","Finasteride, Tablet, 5 mg (NDC 0093-7355-56)",New,8/19/25,,Discontinuation of the manufacture of the drug product,,,Urology,To Be Discontinued,,8/19/25
14216,Finasteride Tablet,"Teva Pharmaceuticals USA, Inc.","Finasteride, Tablet, 5 mg (NDC 0093-7355-98)",New,8/19/25,,Discontinuation of the manufacture of the drug product,,,Urology,To Be Discontinued,,8/19/25
14217,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 100 mg (NDC 0049-3420-30)",New,9/27/24,,Discontinuation Of The Manufacture Of The Drug,,,Anti-Infective,To Be Discontinued,,9/27/24
14218,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 200 mg (NDC 0049-3430-30)",New,9/27/24,,Discontinuation Of The Manufacture Of The Drug,,,Anti-Infective,To Be Discontinued,,9/27/24
14219,Fluoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Prozac, Capsule, 10 mg (NDC 0777-3104-02)",New,10/3/24,,,,,Psychiatry,To Be Discontinued,,10/3/24
14220,Fluoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Prozac, Capsule, 20 mg (NDC 0777-3105-02)",New,10/3/24,,,,,Psychiatry,To Be Discontinued,,10/3/24
14221,Fluoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Prozac, Capsule, 20 mg (NDC 0777-3105-30)",New,10/3/24,,,,,Psychiatry,To Be Discontinued,,10/3/24
14222,Fluoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Prozac, Capsule, 40 mg (NDC 0777-3107-30)",New,10/3/24,,,,,Psychiatry,To Be Discontinued,,10/3/24
14223,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)",Reverified,8/19/25,Available,,,,Neurology; Other,Current,,
14224,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)",Reverified,8/19/25,Available,,,,Neurology; Other,Current,,
14225,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)",Reverified,8/19/25,Available,,,,Oncology; Other,Current,,
14226,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)",Reverified,8/19/25,Available,,,,Neurology; Other,Current,,
14227,Flurazepam Hydrochloride Capsule,"Rising Pharma Holdings, Inc.","Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)",Reverified,8/19/25,Unavailable,Anticipated availability: Q3 2025; Delay is due to manufacturing delays at the contract manufacturing facility.,,Regulatory delay,Neurology; Other,Current,,
14228,Flurazepam Hydrochloride Capsule,"Rising Pharma Holdings, Inc.","Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)",Reverified,8/19/25,Unavailable,Anticipated availability: Q3 2025; Delay is due to manufacturing delays at the contract manufacturing facility.,,Regulatory delay,Neurology; Other,Current,,
14229,Flurbiprofen Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 100 mg (NDC 0093-0711-01)",New,11/13/24,,A business decision was made to discontinue manufacture of the product.,,,Analgesia/Addiction,To Be Discontinued,,11/13/24
14230,Flurbiprofen Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 100 mg (NDC 0093-0711-05)",New,11/13/24,,A business decision was made to discontinue manufacture of the product.,,,Analgesia/Addiction,To Be Discontinued,,11/13/24
14231,Fluticasone Propionate; Salmeterol Xinafoate Powder,"Teva Pharmaceuticals USA, Inc.","AirDuo RespiClick, Powder, 55 ug; 14 ug (NDC 59310-805-06)",New,6/13/25,,,,,Pulmonary/Allergy,To Be Discontinued,,6/13/25
14232,Fluticasone Propionate; Salmeterol Xinafoate Powder,"Teva Pharmaceuticals USA, Inc.","AirDuo RespiClick, Powder, 113 ug; 14 ug (NDC 59310-812-06)",New,6/13/25,,,,,Pulmonary/Allergy,To Be Discontinued,,6/13/25
14233,Fluticasone Propionate; Salmeterol Xinafoate Powder,"Teva Pharmaceuticals USA, Inc.","AirDuo RespiClick, Powder, 232 ug; 14 ug (NDC 59310-822-06)",New,6/13/25,,,,,Pulmonary/Allergy,To Be Discontinued,,6/13/25
14234,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2027,,Other,Cardiovascular,Current,,
14235,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,
14236,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,
14237,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,
14238,Furosemide Injection,Accord Healthcare Inc.,"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)",Revised,8/19/25,Unavailable,Estimated recovery: TBD,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,
14239,Furosemide Injection,Accord Healthcare Inc.,"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)",Revised,8/19/25,Unavailable,Estimated recovery: TBD,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,
14240,Furosemide Injection,Accord Healthcare Inc.,"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)",Revised,8/19/25,Unavailable,Estimated recovery: TBD,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,
14241,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL; 2mL vial (NDC 83634-302-02)",Reverified,9/3/25,Available,Distributed by Avenacy; Contact information: 877-283-6229,,,Cardiovascular,Current,,
14242,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL; 4mL vial (NDC 83634-302-04)",Reverified,9/3/25,Available,Distributed by Avenacy; Contact information: 877-283-6229,,,Cardiovascular,Current,,
14243,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 83634-302-10)",Reverified,9/3/25,Available,Distributed by Avenacy; Contact information: 877-283-6229,,,Cardiovascular,Current,,
14244,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-02)",Reverified,8/26/25,"Unavailable, Please use Sagent label",Use Sagent NDC 25021-311-02,,Other,Cardiovascular,Current,,
14245,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-04)",Reverified,8/26/25,Unavailable,Use Sagent NDC 25021-311-04,,Other,Cardiovascular,Current,,
14246,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-10)",Reverified,8/26/25,"Unavailable, Please use Sagent label",Use Sagent NDC 25021-311-10,,Other,Cardiovascular,Current,,
14247,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)",Reverified,8/26/25,Available,,,,Cardiovascular,Current,,
14248,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)",Reverified,8/26/25,Available,,,,Cardiovascular,Current,,
14249,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)",Reverified,8/26/25,Available,,,,Cardiovascular,Current,,
14250,Furosemide Injection,"Fresenius Kabi USA, LLC","Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,
14251,Furosemide Injection,"Fresenius Kabi USA, LLC","Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,
14252,Furosemide Injection,"Fresenius Kabi USA, LLC","Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,
14253,Furosemide Injection,Eugia US LLC,"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,
14254,Furosemide Injection,Eugia US LLC,"Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,
14255,Furosemide Injection,Eugia US LLC,"Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,
14256,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)",Reverified,9/3/25,Unavailable,Estimated recovery: end of 2025,,Other,Cardiovascular,Current,,
14257,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,
14258,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)",Reverified,9/3/25,Limited Availability,On allocation through Q3 2025,,Other,Cardiovascular,Current,,
14259,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,
14260,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,
14261,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,
14262,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: September 2025,,Other,Cardiovascular,Current,,
14263,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2025,,Other,Cardiovascular,Current,,
14264,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)",Reverified,8/15/25,Available,,,,Cardiovascular,Current,,
14265,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2027,,Other,Cardiovascular,Current,,
14266,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2027,,Other,Cardiovascular,Current,,
14267,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Cardiovascular,Current,,
14268,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Cardiovascular,Current,,
14269,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Cardiovascular,Current,,
14270,Gefitinib Tablet,Apotex Corp.,"Gefitinib, Tablet, 250 mg (NDC 60505-4512-3)",New,2/5/25,,,,,Oncology,To Be Discontinued,,2/5/25
14271,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 5 mg (NDC 0591-0844-01)",New,2/6/25,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/25
14272,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 5 mg (NDC 0591-0844-10)",New,2/6/25,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/25
14273,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 10 mg (NDC 0591-0845-01)",New,2/6/25,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/25
14274,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 10 mg (NDC 0591-0845-10)",New,2/6/25,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/25
14275,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 2.5 mg (NDC 0591-0900-30)",New,2/6/25,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/25
14276,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glucotrol XL, Tablet, Extended Release, 5 mg (NDC 0049-0174-03)",New,3/17/25,,Supply expected to exhaust early April 2025,,,Endocrinology/Metabolism,To Be Discontinued,,3/17/25
14277,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glucatrol XL, Tablet, Extended Release, 10 mg tablets; bottle of 500 (NDC 0049-0178-08)",New,7/24/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/24/25
14278,Glyburide Tablet,"Teva Pharmaceuticals USA, Inc.","Glyburide (Micronized), Tablet, 1.5 mg (NDC 0093-8034-01)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,6/10/25
14279,Glyburide Tablet,"Teva Pharmaceuticals USA, Inc.","Glyburide (Micronized), Tablet, 3 mg (NDC 0093-8035-01)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,6/10/25
14280,Glyburide Tablet,"Teva Pharmaceuticals USA, Inc.","Glyburide (Micronized), Tablet, 3 mg (NDC 0093-8035-05)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,6/10/25
14281,Glyburide Tablet,"Teva Pharmaceuticals USA, Inc.","Glyburide (Micronized), Tablet, 6 mg (NDC 0093-8036-01)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,6/10/25
14282,Haloperidol Decanoate Injection,Janssen Pharmaceuticals,"Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 10147-0921-3)",New,4/7/25,,Marketed by Patriot Pharmaceuticals LLC; Last batch expiration date 5/31/2025,,,Psychiatry,To Be Discontinued,,4/7/25
14283,Haloperidol Decanoate Injection,Janssen Pharmaceuticals,"Haloperidol Decanoate, Injection, 100 mg/1 mL (NDC 10147-0922-5)",New,4/7/25,,Marketed by Patriot Pharmaceuticals LLC; Last batch expiration date 10/31/2025,,,Psychiatry,To Be Discontinued,,4/7/25
14284,Haloperidol Decanoate Injection,Janssen Pharmaceuticals,"Haldol, Injection, 50 mg/1 mL (NDC 50458-253-03)",New,4/7/25,,Last batch expiration date 5/31/2025,,,Psychiatry,To Be Discontinued,,4/7/25
14285,Haloperidol Decanoate Injection,Janssen Pharmaceuticals,"Haldol, Injection, 100 mg/1 mL (NDC 50458-254-14)",New,4/7/25,,Last batch expiration date 8/31/2025,,,Psychiatry,To Be Discontinued,,4/7/25
14286,Heparin Sodium Injection,"Hospira, Inc., a Pfizer Company","Heparin Sodium, Injection, 5000 [USP'U]/1 mL (NDC 0409-1402-12)",New,4/29/25,,Discontinuation of the manufacture of the drug.,,,Hematology,To Be Discontinued,,4/29/25
14287,Heparin Sodium Injection,B. Braun Medical Inc.,"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)",Reverified,8/21/25,Available,,,,Hematology,Current,,
14288,Heparin Sodium Injection,"Fresenius Kabi USA, LLC","Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Hematology,Current,,
14289,Heparin Sodium Injection,"Fresenius Kabi USA, LLC","Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Hematology,Current,,
14290,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0424-18)",Reverified,9/3/25,Unavailable,Product Discontinued - Product code AHB0953U replaced by Product Code 2B0953,,Discontinuation of the manufacture of the drug,Hematology,Current,,
14291,Heparin Sodium Injection,B. Braun Medical Inc.,"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)",Reverified,8/21/25,Available,,,,Hematology,Current,,
14292,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)",Reverified,9/3/25,Available,,,,Hematology,Current,,
14293,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)",Reverified,9/3/25,Limited Availability,Recovery TBD,,Demand increase for the drug,Hematology,Current,,
14294,Heparin Sodium Injection,"Hospira, Inc., a Pfizer Company","Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)",Reverified,8/15/25,Available,,,,Hematology,Current,1/2/25,
14295,Heparin Sodium Injection,"Hospira, Inc., a Pfizer Company","Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)",Reverified,8/15/25,Available,,,,Hematology,Current,1/2/25,
14296,Hydrocortisone Cream,"Teva Pharmaceuticals USA, Inc.","Hydrocortisone, Cream, 10 mg/1 g (NDC 0472-0321-26)",New,3/24/25,,A business decision was made to discontinue.,,,Dermatology,To Be Discontinued,,3/24/25
14297,Hydrocortisone Cream,"Teva Pharmaceuticals USA, Inc.","Hydrocortisone, Cream, 25 mg/1 g (NDC 0472-0337-20)",New,3/24/25,,A business decision was made to discontinue.,,,Dermatology,To Be Discontinued,,3/24/25
14298,Hydrocortisone Cream,"Teva Pharmaceuticals USA, Inc.","Hydrocortisone, Cream, 25 mg/1 g (NDC 0472-0337-30)",New,3/24/25,,A business decision was made to discontinue.,,,Dermatology,To Be Discontinued,,3/24/25
14299,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 1000 mg/vial (NDC 0009-0005-01)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,
14300,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 100 mg/vial (NDC 0009-0825-01)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,
14301,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 100 mg/vial (NDC 0009-0011-04)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,12/19/24,
14302,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-Cortef, Injection, 100 mg/vial (NDC 0009-0011-03)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,12/19/24,
14303,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-06)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,
14304,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-05)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,
14305,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 500 mg/vial (NDC 0009-0016-12)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,
14306,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,,
14307,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)",Revised,8/15/25,Unavailable,Next Delivery: February 2026; Estimated Recovery: March 2026,,Other,Analgesia/Addiction,Current,,
14308,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Analgesia/Addiction,Current,,
14309,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)",Reverified,9/2/25,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,
14310,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)",Revised,8/19/25,Available,Estimated recovery: November 2025,,Shortage of an active ingredient,Analgesia/Addiction,Current,,
14311,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)",Revised,8/19/25,Available,Estimated recovery: November 2025,,Shortage of an active ingredient,Analgesia/Addiction,Current,,
14312,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)",Revised,8/19/25,Available,Estimated recovery: November 2025,,Shortage of an active ingredient,Analgesia/Addiction,Current,,
14313,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)",Revised,7/23/25,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction,Current,1/3/25,
14314,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)",Revised,7/23/25,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction,Current,,
14315,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: September 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,1/2/25,
14316,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/2/25,
14317,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/2/25,
14318,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Injection, 1 mg/1 mL (NDC 0409-2552-01)",Revised,1/13/25,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction,To Be Discontinued,1/13/25,1/13/25
14319,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/2/25,
14320,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/2/25,
14321,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/2/25,
14322,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,
14323,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,
14324,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesaler for inventory.,,Other,Analgesia/Addiction,Current,,
14325,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesaler for inventory.,,Demand increase for the drug,Analgesia/Addiction,Current,,
14326,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesaler for inventory.,,Other,Analgesia/Addiction,Current,,
14327,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,
14328,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,
14329,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)",Revised,9/2/25,Available,Check wholesalers for inventory,,Other,Analgesia/Addiction,Current,,
14330,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,
14331,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect‚Äö√Ñ√∂‚àö√´¬¨¬¢ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)",Revised,8/15/25,Unavailable,Next Delivery: August 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Analgesia/Addiction,Current,,
14332,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect‚Äö√Ñ√∂‚àö√´¬¨¬¢ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,,
14333,Hydroxocobalamin Injection,BTG International Inc.,"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)",Revised,8/5/25,Limited Availability,"Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches available to U.S. patients during this period of shortage.",,Requirements related to complying with good manufacturing practices,Other,Current,,
14334,Hydroxypropyl Cellulose (1600000 Wamw) Insert,Bausch & Lomb Incorporated,"Lacrisert, Insert, 5 mg (NDC 24208-800-60)",Revised,7/16/25,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,,
14335,Ibandronate Sodium Injection,Norvium Bioscience LLC,"Ibandronate Sodium, Injection, 3 mg/3 mL (NDC 67457-524-33)",New,3/5/25,,,,,Endocrinology/Metabolism,To Be Discontinued,,3/5/25
14336,Ibutilide Fumarate Injection,Norvium Bioscience LLC,"Ibutilide Fumarate, Injection, .1 mg/1 mL (NDC 67457-366-10)",New,3/5/25,,,,,Cardiovascular,To Be Discontinued,,3/5/25
14337,Idarubicin Hydrochloride Injection,Pfizer Inc.,"Idamycin, Injection, 1 mg/1 mL (NDC 0013-2576-91)",New,2/6/25,,Replaced with NDC 0013-2576-05,,,Oncology,To Be Discontinued,,2/6/25
14338,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-13)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24
14339,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-81)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24
14340,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-83)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24
14341,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-88)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24
14342,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-13)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24
14343,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-64)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24
14344,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-83)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24
14345,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-88)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24
14346,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 68001-490-05)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24
14347,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 68001-491-04)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24
14348,Indium In-111 Chloride  Injection,Curium US LLC,"Injection, 0.5 mL/vial (5 mCi at time of calibration) (NDC 69945-132-06)",New,9/24/24,,Product discontinued due to business related reasons,,,Medical Imaging,To Be Discontinued,,9/24/24
14349,Indocyanine Green Injection,Renew Pharmaceuticals Limited,"Indocyanine Green, Injection, 25 mg (NDC 70100-424-02)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,
14350,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-936-15)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,
14351,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-903-14)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,
14352,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-306-13)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,
14353,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-936-25)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,
14354,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-903-24)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,
14355,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-306-23)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,
14356,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-937-16)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,
14357,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-937-26)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,
14358,Indocyanine Green Injection,Renew Pharmaceuticals Limited,"IC-GREEN, Injection, 25 mg (NDC 70100-825-02)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,
14359,Insulin Aspart Injection,"Novo Nordisk, Inc.","Insulin Aspart, Injection, 10 mL Insulin Aspart vial (NDC 73070-100-11)",New,7/21/25,,"Unbranded Insulin Aspart 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25
14360,Insulin Aspart Injection,"Novo Nordisk, Inc.","Insulin Aspart, Injection, 3 mL Insulin Aspart PenFill¬¨¬®‚àö√ú cartridge (NDC 73070-102-15)",New,7/21/25,,"Unbranded Insulin Aspart 3 mL PenFill¬¨¬®‚àö√ú cartridge will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25
14361,Insulin Aspart Injection,"Novo Nordisk, Inc.","Insulin Aspart, Injection, 3 mL Insulin Aspart FlexPen¬¨¬®‚àö√ú (NDC 73070-103-15)",New,7/21/25,,"Unbranded Insulin Aspart 3 mL FlexPen¬¨¬®‚àö√ú will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25
14362,Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension,"Novo Nordisk, Inc.","Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 10 mL Insulin aspart protamine and insulin aspart Mix 70/30 vial (NDC 73070-200-11)",New,7/21/25,,"Unbranded Insulin Aspart Protamine and Insulin Aspart Mix 70/30 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25
14363,Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension,"Novo Nordisk, Inc.","Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 3 mL vial Insulin aspart protamine and insulin aspart Mix 70/30 FlexPen¬¨¬®‚àö√ú (NDC 73070-203-15)",New,7/21/25,,"Unbranded Insulin aspart protamine and insulin aspart FlexPen¬¨¬®‚àö√ú will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25
14364,Insulin Degludec Injection,"Novo Nordisk, Inc.","Insulin Degludec, Injection, 10 mL Insulin Degludec vial (NDC 73070-400-11)",New,7/21/25,,"Unbranded Insulin Degludec 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25
14365,Insulin Degludec Injection,"Novo Nordisk, Inc.","Insulin Degludec, Injection, 3 mL Insulin Degludec 100 units/mL (U-100) FlexTouch¬¨¬®‚àö√ú (NDC 73070-403-15)",New,7/21/25,,"Unbranded Insulin Degludec 3 mL U-100 FlexTouch¬¨¬®‚àö√ú will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25
14366,Insulin Degludec Injection,"Novo Nordisk, Inc.","Insulin Degludec, Injection, 3 mL Insulin Degludec 200 units/mL (U-200) FlexTouch¬¨¬®‚àö√ú (NDC 73070-503-15)",New,7/21/25,,"Unbranded Insulin Degludec 3 mL U-200 FlexTouch¬¨¬®‚àö√ú will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25
14367,Ipratropium Bromide Solution,"Sun Pharmaceutical Industries, Inc.","Solution, .5 mg/2.5 mL (NDC 47335-706-49)",New,9/20/24,,,,,Pulmonary/Allergy,To Be Discontinued,,9/20/24
14368,Ipratropium Bromide Solution,"Sun Pharmaceutical Industries, Inc.","Solution, .5 mg/2.5 mL (NDC 47335-706-52)",New,9/20/24,,,,,Pulmonary/Allergy,To Be Discontinued,,9/20/24
14369,Ipratropium Bromide Solution,"Sun Pharmaceutical Industries, Inc.","Solution, .5 mg/2.5 mL (NDC 47335-706-54)",New,9/20/24,,,,,Pulmonary/Allergy,To Be Discontinued,,9/20/24
14370,Irinotecan Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-51)",New,8/4/25,,Product not anticipated to be available beyond mid-late October 2025,,,Oncology,To Be Discontinued,,8/4/25
14371,Irinotecan Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-55)",New,8/4/25,,Product not anticipated to be available beyond mid-late September 2025,,,Oncology,To Be Discontinued,,8/4/25
14372,Irinotecan Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 40 mg per 2 mL (20mg per mL) (NDC 63323-193-52)",New,9/30/24,,,,,Oncology,To Be Discontinued,,9/30/24
14373,Irinotecan Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg per 5 mL (20mg per mL) (NDC 63323-193-55)",New,9/30/24,,,,,Oncology,To Be Discontinued,,9/30/24
14374,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 100 mg (NDC 0555-0066-02)",New,11/21/24,,Product available through 12/03/2024,,,Anti-Infective,To Be Discontinued,,11/21/24
14375,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 300 mg (NDC 0555-0071-01)",New,11/21/24,,Product available through 12/03/2024,,,Anti-Infective,To Be Discontinued,,11/21/24
14376,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 300 mg (NDC 0555-0071-02)",New,11/21/24,,Product available through 12/03/2024,,,Anti-Infective,To Be Discontinued,,11/21/24
14377,Isoniazid Tablet,Genus Lifesciences,"Isoniazid, Tablet, 300 mg (NDC 64950-217-03)",New,7/1/25,,Product expected to be available until August 2025.,,,Anti-Infective,To Be Discontinued,,7/1/25
14378,Isoniazid Tablet,Genus Lifesciences,"Isoniazid, Tablet, 300 mg (NDC 64950-217-10)",New,7/1/25,,Product expected to be available until August 2025.,,,Anti-Infective,To Be Discontinued,,7/1/25
14379,Isosorbide Mononitrate Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 20 mg (NDC 0228-2620-11)",New,11/13/24,,A business decision was made to discontinue manufacture of this product.,,,Cardiovascular,To Be Discontinued,,11/13/24
14380,Isosorbide Mononitrate Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 10 mg (NDC 0228-2631-11)",New,11/13/24,,A business decision was made to discontinue manufacture of this product.,,,Cardiovascular,To Be Discontinued,,11/13/24
14381,Ketamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Ketamine Hydrochloride, Injection, 500 mg/5 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 0409-2051-05)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14382,Ketamine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Ketamine Hydrochloride, Injection, 10 mg/1 mL (NDC 65219-184-20)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14383,Ketamine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 65219-188-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14384,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 10 mg/1 mL (NDC 25021-682-20)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14385,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 25021-683-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14386,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 100 mg/1 mL (NDC 25021-684-05)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14387,Ketamine Hydrochloride Injection,Eugia US LLC,"Ketamine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-438-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14388,Ketamine Hydrochloride Injection,Eugia US LLC,"Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 55150-439-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14389,Ketamine Hydrochloride Injection,Eugia US LLC,"Ketamine Hydrochloride, Injection, 100 mg/1 mL (NDC 55150-440-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14390,Ketamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Ketamine Hydrochloride, Injection, 500 mg/5 mL (100 mg/mL) (NDC 0409-0040-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14391,Ketamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Ketamine Hydrochloride, Injection, 500 mg/10 mL (50 mg/mL) (NDC 0409-2053-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14392,Ketamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Ketamine Hydrochloride, Injection, 100 mg/1 mL (NDC 0143-9509-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14393,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 10 mg/1 mL (NDC 42023-113-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14394,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 100 mg/1 mL (NDC 42023-115-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14395,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 50 mg/1 mL (NDC 42023-114-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14396,Ketamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 0143-9508-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,
14397,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)",Reverified,8/26/25,Available,,,,Analgesia/Addiction,Current,,
14398,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)",Reverified,8/26/25,Available,,,,Analgesia/Addiction,Current,,
14399,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)",Reverified,8/26/25,Available,,,,Analgesia/Addiction,Current,,
14400,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Analgesia/Addiction,Current,,
14401,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,,
14402,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Analgesia/Addiction,Current,,
14403,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc.","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)",Revised,7/23/25,Unavailable,Shortage recovery: TBD,,Other,Analgesia/Addiction,Current,,
14404,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc.","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)",Revised,7/23/25,Unavailable,Shortage recovery: TBD,,Other,Analgesia/Addiction,Current,,
14405,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc.","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)",Revised,7/23/25,Unavailable,Shortage recovery: TBD,,Other,Analgesia/Addiction,Current,,
14406,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)",Reverified,9/2/25,Available,Check wholesaler inventory,,,Analgesia/Addiction,Current,,
14407,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)",Reverified,9/2/25,Available,Check wholesaler inventory,,,Analgesia/Addiction,Current,,
14408,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)",Reverified,9/2/25,Available,Check wholesaler inventory,,,Analgesia/Addiction,Current,,
14409,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)",Reverified,9/3/25,Available,,,,Analgesia/Addiction,Current,,
14410,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)",Reverified,9/3/25,Available,,,,Analgesia/Addiction,Current,,
14411,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)",Reverified,9/2/25,Unavailable,Not available at this time.,,Other,Analgesia/Addiction,Current,,
14412,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)",Reverified,9/2/25,Unavailable,Not available at this time.,,Other,Analgesia/Addiction,Current,,
14413,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)",Reverified,9/2/25,Unavailable,Not available at this time.,,Other,Analgesia/Addiction,Current,,
14414,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)",Reverified,7/28/25,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Analgesia/Addiction,Current,,
14415,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)",Reverified,7/28/25,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Analgesia/Addiction,Current,,
14416,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)",Reverified,6/27/25,Available,,,,Analgesia/Addiction,Current,,
14417,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)",Reverified,6/27/25,Available,,,,Analgesia/Addiction,Current,,
14418,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)",Reverified,6/27/25,Available,,,,Analgesia/Addiction,Current,,
14419,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 70860-701-03)",Reverified,7/28/25,Available,"Athenex is not active, supplying through Sagent NDC 25021-701-01",,,Analgesia/Addiction,Current,,
14420,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 70860-700-02)",Reverified,7/28/25,Available,"Athenex is not active, supplying through Sagent NDC  25021-700-01",,,Analgesia/Addiction,Current,,
14421,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 70860-701-04)",Reverified,7/28/25,Available,"Athenex is not active, supplying through Sagent NDC 25021-701-02",,,Analgesia/Addiction,Current,,
14422,Lactated Ringers Injection,Otsuka ICU Medical LLC,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-02)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,
14423,Lactated Ringers Injection,Otsuka ICU Medical LLC,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-03)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,
14424,Lactated Ringers Injection,Otsuka ICU Medical LLC,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-09)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,
14425,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0117-04)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,
14426,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 250 mL bag, 36 count (NDC 0338-0117-02)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,
14427,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 500 mL bag, 24 count (NDC 0338-0117-03)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,
14428,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 20 mg/100 mL; 5 g/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0125-04)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,
14429,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 20 mg/100 mL; 5 g/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0125-03)",Reverified,9/3/25,Unavailable,Product Discontinued,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism; Gastroenterology; Other,Current,,
14430,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7500-00)",Reverified,8/21/25,Unavailable,Product not yet launched,,Other,Endocrinology/Metabolism; Gastroenterology; Other,Current,,
14431,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-00)",Revised,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,
14432,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-10)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,
14433,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-20)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,
14434,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; 5 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7751-00)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,
14435,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; 5 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7751-10)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,
14436,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 350 mg (NDC 70436-119-80)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14437,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 50 mg (NDC 70436-116-82)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14438,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 100 mg (NDC 70436-117-80)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14439,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 200 mg (NDC 70436-118-80)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14440,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 500 mg (NDC 70436-120-80)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14441,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 25021-813-10)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14442,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 25021-814-30)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14443,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 25021-815-30)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14444,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 25021-816-30)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14445,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 63323-710-50)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14446,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium Preservative Free, Injection, 500 mg/50 mL (NDC 63323-711-00)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14447,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 71288-160-10)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14448,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 71288-161-20)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14449,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 71288-162-30)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14450,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 71288-163-30)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14451,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 500 mg/50 mL (NDC 71288-164-50)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14452,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 0143-9555-01)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14453,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 0143-9554-01)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14454,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 0143-9553-01)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14455,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 0143-9552-01)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14456,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium, Injection, 10 mg/1 mL (NDC 63323-631-10)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14457,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium, Injection, 10 mg/1 mL (NDC 63323-631-50)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14458,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 100 mg/10 mL (NDC 67457-528-10)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14459,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 200 mg/20 mL (NDC 67457-529-20)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14460,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 350 mg/17.5 mL (NDC 67457-530-35)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14461,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium Preservative Free, Injection, 500 mg/50 mL (NDC 25021-828-50)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,
14462,Levalbuterol Hydrochloride Solution,"Teva Pharmaceuticals USA, Inc.","Solution, 1.25 mg/.5 mL (NDC 0093-4147-56)",New,10/15/24,,,,,Pulmonary/Allergy,To Be Discontinued,,10/15/24
14463,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 25 ug (NDC 72305-025-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14464,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 25 ug (NDC 72305-025-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14465,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 50 ug (NDC 72305-050-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14466,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 50 ug (NDC 72305-050-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14467,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 75 ug (NDC 72305-075-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14468,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 75 ug (NDC 72305-075-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14469,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 88 ug (NDC 72305-088-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14470,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 88 ug (NDC 72305-088-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14471,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 100 ug (NDC 72305-100-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14472,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 100 ug (NDC 72305-100-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14473,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 112 ug (NDC 72305-112-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14474,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 112 ug (NDC 72305-112-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14475,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 125 ug (NDC 72305-125-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14476,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 125 ug (NDC 72305-125-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14477,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 137 ug (NDC 72305-137-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14478,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 137 ug (NDC 72305-137-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14479,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 150 ug (NDC 72305-150-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14480,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 150 ug (NDC 72305-150-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14481,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 175 ug (NDC 72305-175-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14482,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 175 ug (NDC 72305-175-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14483,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 200 ug (NDC 72305-200-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14484,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 200 ug (NDC 72305-200-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25
14485,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
14486,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
14487,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
14488,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
14489,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)",Revised,7/23/25,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Anesthesia,Current,,
14490,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)",Revised,7/23/25,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Anesthesia,Current,,
14491,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)",Revised,7/23/25,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Anesthesia,Current,,
14492,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)",Revised,7/23/25,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Anesthesia,Current,,
14493,Lidocaine Hydrochloride Injection,"Spectra Medical Devices, LLC","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,
14494,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia; Pediatric,Current,,
14495,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)",Reverified,9/2/25,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,
14496,Lidocaine Hydrochloride Injection,Baxter Healthcare,"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,
14497,Lidocaine Hydrochloride Injection,Baxter Healthcare,"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,
14498,Lidocaine Hydrochloride Injection,B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)",Reverified,8/21/25,Available,,,,Cardiovascular,Current,,
14499,Lidocaine Hydrochloride Injection,B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)",Reverified,8/21/25,Available,,,,Cardiovascular,Current,,
14500,Lidocaine Hydrochloride Injection,B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)",Reverified,8/21/25,Available,,,,Cardiovascular,Current,,
14501,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-158-72)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,
14502,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,
14503,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-160-72)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,
14504,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
14505,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
14506,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
14507,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
14508,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
14509,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)",Reverified,9/2/25,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,
14510,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14511,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14512,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14513,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14514,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14515,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14516,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14517,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14518,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14519,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14520,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14521,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14522,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14523,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: September 2025,,Demand increase for the drug,Anesthesia; Pediatric,Current,,
14524,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14525,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)",Revised,8/15/25,Unavailable,Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Anesthesia; Pediatric,Current,12/19/24,
14526,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)",Revised,8/15/25,Unavailable,Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Anesthesia; Pediatric,Current,12/19/24,
14527,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,12/19/24,
14528,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14529,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia; Pediatric,Current,,
14530,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14531,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14532,Lidocaine Hydrochloride Injection,"Amphastar Pharmaceuticals, Inc.","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)",Reverified,8/19/25,Available,old NDC 0548-3390-00,,,Anesthesia; Pediatric,Current,,
14533,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)",Reverified,9/2/25,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,
14534,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)",Reverified,9/2/25,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,
14535,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14536,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14537,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14538,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14539,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14540,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14541,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,
14542,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)",Reverified,9/2/25,Unavailable,Next release date not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,
14543,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)",Revised,8/15/25,Unavailable,Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia; Pediatric,Current,12/19/24,
14544,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14545,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,
14546,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,
14547,Lidocaine Hydrochloride Injection,Afaxys Pharma,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 50102-400-10)",Revised,3/5/25,,,,,Anesthesia; Pediatric,To Be Discontinued,3/5/25,3/5/25
14548,Lidocaine Hydrochloride Injection,"Huons Co., Ltd. (South Korea)","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,
14549,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-001-10)",Reverified,8/19/25,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X2ML) is Preservative free.",,,Anesthesia; Pediatric,Current,,
14550,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-002-10)",Reverified,8/19/25,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X5ML)  is Preservative free.",,,Anesthesia; Pediatric,Current,,
14551,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-003-10)",Reverified,8/19/25,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X10ML) is Preservative free.",,,Anesthesia; Pediatric,Current,,
14552,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-004-10)",Reverified,8/19/25,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X2ML)  is Preservative free.",,,Anesthesia; Pediatric,Current,,
14553,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-005-10)",Reverified,8/19/25,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X5ML)  is Preservative free.",,,Anesthesia; Pediatric,Current,,
14554,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-006-10)",Reverified,8/19/25,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X10ML) is Preservative free.",,,Anesthesia; Pediatric,Current,,
14555,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 40 mg/1 mL (NDC 83090-007-10)",Reverified,8/19/25,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 4% 10X5ML)  is Preservative free.",,,Anesthesia; Pediatric,Current,,
14556,Lidocaine Hydrochloride Solution,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Viscous (Lidocaine Hydrochloride), Solution, 20 mg/1 mL (NDC 0054-3500-49)",Revised,8/29/25,,,Available,,Anesthesia,Resolved,8/29/25,
14557,Lidocaine Hydrochloride Solution,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Viscous (Lidocaine Hydrochloride), Solution, 20 mg/1 mL (NDC 0054-0548-44)",Revised,8/29/25,,,Available,,Anesthesia,Resolved,8/29/25,
14558,Lidocaine Hydrochloride Solution,PAI Pharma,"Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 0121-4950-40)",Revised,8/29/25,,,Available,,Anesthesia,Resolved,8/29/25,
14559,Lidocaine Hydrochloride Solution,Rubicon Research Private Limited,"Lidocaine Hydrochloride, Solution, 20 mg/1 mL (NDC 72888-125-26)",Revised,8/29/25,,,Available,,Anesthesia,Resolved,8/29/25,
14560,Lidocaine Hydrochloride Solution,PAI Pharma,"Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 0121-0950-03)",Revised,8/29/25,,,Available,,Anesthesia,Resolved,8/29/25,
14561,Lidocaine Hydrochloride Solution,Chartwell Molecular Holdings LLC,"Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 62135-712-42)",Revised,8/29/25,,,Available,,Anesthesia,Resolved,8/29/25,
14562,Lidocaine Ointment,Strides Pharma Inc.,"Lidocaine, Ointment, 5%, 30 gram tubes (NDC 64380-789-23)",New,1/28/25,,,,,Anesthesia,To Be Discontinued,,1/28/25
14563,Lidocaine Ointment,Strides Pharma Inc.,"Lidocaine, Ointment, 5%, 35.44 gram tubes (NDC 64380-789-32)",New,1/28/25,,,,,Anesthesia,To Be Discontinued,,1/28/25
14564,Lidocaine Ointment,Strides Pharma Inc.,"Lidocaine, Ointment, 5%, 50 gram jar (NDC 64380-789-33)",New,1/28/25,,,,,Anesthesia,To Be Discontinued,,1/28/25
14565,Lidocaine Patch,"Actavis Pharma, Inc.","Lidocaine, Patch, 5% (NDC 0591-2679-30)",New,7/17/25,,Discontinuation is for the ‚Äö√Ñ√∂‚àö√ë‚àö‚à´NovaPlus‚Äö√Ñ√∂‚àö√ë‚àöœÄ label product only.,,,Analgesia/Addiction,To Be Discontinued,,7/17/25
14566,Linezolid Solution,Pfizer Inc.,"Zyvox, Solution, 600 mg/300 mL (NDC 0009-4992-02)",New,10/11/24,,,,,Anti-Infective,To Be Discontinued,,10/11/24
14567,Linezolid Solution,Pfizer Inc.,"Zyvox, Solution, 200 mg/100 mL (NDC 0009-5137-04)",New,10/11/24,,,,,Anti-Infective,To Be Discontinued,,10/11/24
14568,Liraglutide Injection,"Novo Nordisk, Inc.","Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)",Reverified,7/15/25,Available,,,,Endocrinology/Metabolism,Current,,
14569,Liraglutide Injection,"Hikma Pharmaceuticals USA, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)",Reverified,7/23/25,Available,Product will be made available as it is released.,,,Endocrinology/Metabolism,Current,,
14570,Liraglutide Injection,"Hikma Pharmaceuticals USA, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)",Reverified,7/23/25,Available,Product will be made available as it is released.,,,Endocrinology/Metabolism,Current,,
14571,Liraglutide Injection,"Meitheal Pharmaceuticals, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)",Reverified,8/19/25,Available,,,,Endocrinology/Metabolism,Current,,
14572,Liraglutide Injection,"Meitheal Pharmaceuticals, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)",Reverified,8/19/25,Available,,,,Endocrinology/Metabolism,Current,,
14573,Liraglutide Injection,"Novo Nordisk, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)",Reverified,7/15/25,Available,Distributed by Teva,,,Endocrinology/Metabolism,Current,,
14574,Liraglutide Injection,"Novo Nordisk, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)",Reverified,7/15/25,Available,Distributed by Teva,,,Endocrinology/Metabolism,Current,,
14575,Liraglutide Injection,"Novo Nordisk, Inc.","Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)",Reverified,7/15/25,Limited Availability,Estimated shortage duration TBD,,Delay in shipping of the drug,Endocrinology/Metabolism,Current,,
14576,Liraglutide Injection,"Novo Nordisk, Inc.","Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)",Reverified,7/15/25,Limited Availability,Estimated shortage duration TBD,,Delay in shipping of the drug,Endocrinology/Metabolism,Current,,
14577,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)",Reverified,8/5/25,Available,,,,Psychiatry,Current,,
14578,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)",Reverified,8/5/25,Available,,,,Psychiatry,Current,,
14579,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)",Reverified,8/5/25,Available,,,,Psychiatry,Current,,
14580,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)",Reverified,8/5/25,Available,,,,Psychiatry,Current,,
14581,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)",Reverified,8/5/25,Available,,,,Psychiatry,Current,,
14582,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)",Reverified,8/5/25,Available,,,,Psychiatry,Current,,
14583,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)",Reverified,8/5/25,Available,,,,Psychiatry,Current,,
14584,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
14585,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
14586,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
14587,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
14588,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
14589,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
14590,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
14591,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)",Reverified,7/24/25,Available,Product currently available,,,Psychiatry,Current,,
14592,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)",Reverified,7/24/25,Available,Product currently available,,,Psychiatry,Current,,
14593,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)",Reverified,7/24/25,Available,Product currently available,,,Psychiatry,Current,,
14594,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)",Reverified,7/24/25,Available,Product currently available,,,Psychiatry,Current,,
14595,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)",Reverified,7/24/25,Available,Product currently available,,,Psychiatry,Current,,
14596,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)",Reverified,7/24/25,Limited Availability,"Limited quantity available, next resupply in late July 2025",,Other,Psychiatry,Current,,
14597,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)",Reverified,7/24/25,Limited Availability,"Limited quantity available, next resupply in late July 2025",,Other,Psychiatry,Current,,
14598,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
14599,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
14600,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
14601,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
14602,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
14603,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
14604,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
14605,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,
14606,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,
14607,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,
14608,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,
14609,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,
14610,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,
14611,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,
14612,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,
14613,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,
14614,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,
14615,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,
14616,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,
14617,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,
14618,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,
14619,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)",Reverified,7/23/25,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,
14620,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)",Reverified,7/23/25,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,
14621,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)",Reverified,7/23/25,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,
14622,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)",Reverified,7/23/25,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,
14623,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)",Reverified,7/23/25,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,
14624,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)",Reverified,7/23/25,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,
14625,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)",Reverified,9/2/25,Limited Availability,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,
14626,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)",Reverified,9/2/25,Limited Availability,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,
14627,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)",Revised,9/2/25,Unavailable,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,
14628,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)",Revised,9/2/25,Unavailable,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,
14629,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)",Reverified,9/2/25,Limited Availability,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,
14630,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)",Reverified,9/2/25,Limited Availability,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,
14631,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)",Reverified,9/2/25,Unavailable,Unavailable,,Shortage of an active ingredient,Psychiatry,Current,,
14632,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)",Reverified,8/5/25,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,
14633,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)",Reverified,8/5/25,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,
14634,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)",Reverified,8/5/25,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,
14635,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)",Reverified,8/5/25,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,
14636,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)",Reverified,8/5/25,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,
14637,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)",Reverified,8/5/25,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,
14638,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)",Reverified,8/5/25,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,
14639,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)",Reverified,8/5/25,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,
14640,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)",Reverified,8/5/25,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,
14641,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)",Reverified,8/5/25,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,
14642,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)",Reverified,8/5/25,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,
14643,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)",Reverified,8/5/25,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,
14644,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)",Reverified,8/5/25,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,
14645,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
14646,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
14647,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
14648,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
14649,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
14650,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
14651,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
14652,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)",Reverified,9/2/25,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,
14653,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)",Reverified,9/2/25,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,
14654,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)",Reverified,9/2/25,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,
14655,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)",Reverified,9/2/25,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,
14656,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)",Reverified,9/2/25,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,
14657,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)",Reverified,9/2/25,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,
14658,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)",Reverified,9/2/25,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,
14659,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)",Revised,8/1/25,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,
14660,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
14661,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
14662,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
14663,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
14664,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)",Revised,8/19/25,Limited Availability,Estimated recovery: August 2025,,Shortage of an active ingredient,Psychiatry,Current,,
14665,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
14666,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
14667,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
14668,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
14669,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
14670,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
14671,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
14672,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,
14673,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,
14674,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,
14675,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,
14676,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,
14677,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,
14678,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,
14679,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)",Revised,7/16/25,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,
14680,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)",Revised,7/16/25,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,
14681,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)",Revised,7/16/25,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,
14682,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)",Revised,7/16/25,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,
14683,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)",Revised,7/16/25,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,
14684,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)",Revised,7/16/25,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,
14685,Lodoxamide Tromethamine Solution,Novartis Pharmaceuticals Corporation,"Alomide, Solution, 1 mg/1 mL (NDC 0078-0736-10)",New,12/9/24,,"Novartis has made a business decision to permanently discontinue ALOMIDE¬¨¬®‚àö√ú (lodoxamide tromethamine) ophthalmic solution, 0.1%

Discontinuation of the product is due in part to manufacturing concerns.

Short-dated material is available until January 2025.",,,Ophthalmology,To Be Discontinued,,12/9/24
14686,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,
14687,Lorazepam Injection,"Hospira, Inc., a Pfizer Company","Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)",Revised,8/15/25,Unavailable,Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Neurology,Current,,
14688,Lorazepam Injection,"Amphastar Pharmaceuticals, Inc.","Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)",Reverified,8/19/25,Limited Availability,,,Demand increase for the drug,Neurology,Current,,
14689,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,
14690,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,
14691,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,
14692,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,
14693,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,
14694,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,
14695,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,
14696,Mefloquine Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Mefloquine Hydrochloride, Tablet, 250 mg (NDC 0555-0171-78)",Revised,8/21/25,,,Available,,Anti-Infective,Resolved,8/21/25,
14697,Mefloquine Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Mefloquine Hydrochloride, Tablet, 250 mg (NDC 62135-973-25)",Revised,8/21/25,,,Available,,Anti-Infective,Resolved,8/21/25,
14698,Memantine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Memantine Hydrochloride, Tablet, 5 mg (NDC 0832-1112-60)",New,4/28/25,,,,,Neurology,To Be Discontinued,,4/28/25
14699,Memantine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Memantine Hydrochloride, Tablet, 10 mg (NDC 0832-1113-60)",New,4/28/25,,,,,Neurology,To Be Discontinued,,4/28/25
14700,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, 5 mg (NDC 0591-3870-44)",New,11/21/24,,,,,Neurology,To Be Discontinued,,11/21/24
14701,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, 5 mg (NDC 0591-3870-60)",New,11/21/24,,,,,Neurology,To Be Discontinued,,11/21/24
14702,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, 10 mg (NDC 0591-3875-44)",New,11/21/24,,,,,Neurology,To Be Discontinued,,11/21/24
14703,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, 10 mg (NDC 0591-3875-60)",New,11/21/24,,,,,Neurology,To Be Discontinued,,11/21/24
14704,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, Kit (NDC 0591-3900-87)",New,11/21/24,,,,,Neurology,To Be Discontinued,,11/21/24
14705,Meperidine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)",Revised,7/23/25,Unavailable,Additional Lots scheduled to be available in the October-November 2025 timeframe.,,Shortage of an active ingredient,Analgesia/Addiction,Current,,
14706,Meperidine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)",Revised,7/23/25,Unavailable,Additional Lots scheduled to be available in the October-November 2025 timeframe.,,Shortage of an active ingredient,Analgesia/Addiction,Current,,
14707,Meperidine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)",Revised,7/23/25,Unavailable,Additional Lots scheduled to be available in the October-November 2025 timeframe.,,Shortage of an active ingredient,Analgesia/Addiction,Current,,
14708,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)",Revised,8/15/25,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,,
14709,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)",Revised,8/15/25,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,,
14710,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)",Revised,8/15/25,Unavailable,Next Delivery and Estimated Recovery: September 2025,,Demand increase for the drug,Analgesia/Addiction,Current,,
14711,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)",Revised,8/15/25,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,
14712,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)",Revised,8/15/25,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,
14713,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)",Revised,8/15/25,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,
14714,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)",Revised,8/15/25,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,
14715,Methamphetamine Hydrochloride Tablet,"Dr. Reddy's Laboratories, Inc.","Methamphetamine Hydrochloride, Tablet, 5 mg (NDC 68308-115-01)",Reverified,8/15/25,Available,Available to existing customers,,,Psychiatry,Current,,
14716,Methamphetamine Hydrochloride Tablet,"Hikma Pharmaceuticals USA, Inc.","Methamphetamine Hydrochloride, Tablet, 5 mg (NDC 0054-0389-25)",Revised,8/1/25,Available,,,,Psychiatry,Current,,
14717,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 10 mg/.4 mL (NDC 82497-010-04)",New,8/29/25,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/25
14718,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 12.5 mg/.4 mL (NDC 82497-012-04)",New,8/29/25,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/25
14719,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 15 mg/.4 mL (NDC 82497-015-04)",New,8/29/25,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/25
14720,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 17.5 mg/.4 mL (NDC 82497-017-04)",New,8/29/25,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/25
14721,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 20 mg/.4 mL (NDC 82497-020-04)",New,8/29/25,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/25
14722,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 22.5 mg/.4 mL (NDC 82497-022-04)",New,8/29/25,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/25
14723,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 25 mg/.4 mL (NDC 82497-025-04)",New,8/29/25,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/25
14724,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Injection, 25 mg/1 mL (NDC 61703-161-05)",New,1/8/25,,Discontinuation of the manufacture of the drug,,,Oncology; Rheumatology,To Be Discontinued,,1/8/25
14725,Methotrexate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)",Reverified,7/23/25,Available,Currently available.  Additional product will be made available as it is released.,,,Rheumatology; Oncology,Current,,
14726,Methotrexate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Rheumatology; Oncology,Current,,
14727,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)",Revised,8/19/25,Available,Estimated recovery: December 2025,,Other,Rheumatology; Oncology,Current,,
14728,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)",Revised,8/19/25,Unavailable,Estimated recovery: October 2025,,Other,Rheumatology; Oncology,Current,,
14729,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)",Revised,8/19/25,Limited Availability,Estimated recovery: January 2026,,Other,Rheumatology; Oncology,Current,,
14730,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)",Reverified,8/15/25,Available,,,,Rheumatology; Oncology,Current,,
14731,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 50 mg/2 mL  (25 mg/mL) (NDC 61703-350-10)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Rheumatology; Oncology,Current,,
14732,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)",Reverified,8/15/25,Available,,,,Rheumatology; Oncology,Current,,
14733,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)",Reverified,8/15/25,Available,,,,Rheumatology; Oncology,Current,,
14734,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)",Reverified,8/15/25,Available,,,,Rheumatology; Oncology,Current,,
14735,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)",Reverified,9/2/25,Available,Check wholesaler for inventory,,,Rheumatology; Oncology,Current,,
14736,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)",Reverified,9/2/25,Available,Check whlolesaler for inventory,,,Rheumatology; Oncology,Current,,
14737,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)",Revised,8/19/25,Unavailable,Resupply: estimated 14 days,,Shortage of an active ingredient,Rheumatology; Oncology,Current,,
14738,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)",Revised,8/19/25,Unavailable,Resupply: estimated 14 days,,Shortage of an active ingredient,Rheumatology; Oncology,Current,,
14739,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Daytrana, Film, Extended Release, 10 mg (NDC 68968-5552-3)",Reverified,8/19/25,Unavailable,Estimated availability TBD,,Shortage of an active ingredient,Psychiatry,Current,,
14740,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Daytrana, Film, Extended Release, 15 mg (NDC 68968-5553-3)",Reverified,8/19/25,Unavailable,Estimated availability TBD,,Shortage of an active ingredient,Psychiatry,Current,,
14741,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Daytrana, Film, Extended Release, 20 mg (NDC 68968-5554-3)",Reverified,8/19/25,Unavailable,Estimated availability TBD,,Shortage of an active ingredient,Psychiatry,Current,,
14742,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Daytrana, Film, Extended Release, 30 mg (NDC 68968-5555-3)",Reverified,8/19/25,Unavailable,Estimated availability TBD,,Shortage of an active ingredient,Psychiatry,Current,,
14743,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)",Revised,8/19/25,Available,Available. Distributed by Padagis US LLC,,,Psychiatry,Current,,
14744,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)",Revised,8/19/25,Unavailable,Estimated availability: end October 2025. Distributed by Padagis US LLC,,Shortage of an active ingredient,Psychiatry,Current,,
14745,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)",Revised,8/19/25,Unavailable,Estimated availability: early September 2025. Distributed by Padagis US LLC,,Shortage of an active ingredient,Psychiatry,Current,,
14746,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)",Revised,8/19/25,Unavailable,Estimated availability: early September 2025. Distributed by Padagis US LLC,,Shortage of an active ingredient,Psychiatry,Current,,
14747,"Methylphenidate Film, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Methylphenidate, Film, Extended Release, 10mg/9hrs (NDC 0378-8260-93)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
14748,"Methylphenidate Film, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Methylphenidate, Film, Extended Release, 15mg/9hrs (NDC 0378-8261-93)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
14749,"Methylphenidate Film, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Methylphenidate, Film, Extended Release, 20mg/9hrs (NDC 0378-8262-93)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
14750,"Methylphenidate Film, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Methylphenidate, Film, Extended Release, 30mg/9hrs (NDC 0378-8263-93)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,
14751,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)",Reverified,9/4/25,Available,,,,Psychiatry,Current,,
14752,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)",Reverified,9/4/25,Available,,,,Psychiatry,Current,,
14753,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)",Reverified,9/4/25,Available,,,,Psychiatry,Current,,
14754,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)",Reverified,9/4/25,Available,,,,Psychiatry,Current,,
14755,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)",Reverified,9/4/25,Unavailable,Estimated recovery: TBD,,Other,Psychiatry,Current,,
14756,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)",Reverified,9/4/25,Unavailable,Estimated recovery: TBD,,Other,Psychiatry,Current,,
14757,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)",Reverified,9/4/25,Unavailable,Estimated recovery: TBD,,Other,Psychiatry,Current,,
14758,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)",Reverified,9/4/25,Available,,,,Psychiatry,Current,,
14759,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)",Reverified,9/4/25,Unavailable,Estimated recovery: TBD,,Other,Psychiatry,Current,,
14760,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)",Reverified,9/4/25,Available,,,,Psychiatry,Current,,
14761,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)",Reverified,9/4/25,Available,,,,Psychiatry,Current,,
14762,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylin Er, Tablet, Extended Release, 10 mg (NDC 0406-1445-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,
14763,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylin Er, Tablet, Extended Release, 20 mg (NDC 0406-1473-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers. Short term backorder expected in September with recovery in October 2025.,,Shortage of an active ingredient,Psychiatry,Current,,
14764,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 0406-0127-01)",Revised,9/2/25,Unavailable,Backorder expected with next release expected in October 2025.,,Shortage of an active ingredient,Psychiatry,Current,,
14765,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 0406-0136-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers. Short term backorder expected in September with recovery in October 2025.,,Shortage of an active ingredient,Psychiatry,Current,,
14766,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 0406-0154-01)",Reverified,9/2/25,Unavailable,Backorder. Next release expected in October 2025.,,Shortage of an active ingredient,Psychiatry,Current,,
14767,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
14768,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
14769,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)",Reverified,9/2/25,Unavailable,other,,Other,Psychiatry,Current,,
14770,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
14771,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 18 mg (NDC 62037-725-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
14772,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 27 mg (NDC 62037-734-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
14773,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 36 mg (NDC 62037-726-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
14774,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 54 mg (NDC 62037-727-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,
14775,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 43598-438-01)",Reverified,8/15/25,Unavailable,Estimated availability TBD,,Other,Psychiatry,Current,,
14776,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 43598-439-01)",Reverified,8/15/25,Unavailable,Estimated availability TBD,,Other,Psychiatry,Current,,
14777,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 43598-440-01)",Reverified,8/15/25,Available,Available to existing customers,,,Psychiatry,Current,,
14778,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 43598-441-01)",Reverified,8/15/25,Unavailable,Estimated availability TBD,,Other,Psychiatry,Current,,
14779,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)",Reverified,9/4/25,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,
14780,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)",Reverified,9/4/25,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,
14781,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)",Reverified,9/4/25,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,
14782,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)",Reverified,9/4/25,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,
14783,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)",Reverified,9/4/25,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,
14784,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)",Reverified,9/4/25,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,
14785,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)",Reverified,9/4/25,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,
14786,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
14787,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
14788,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
14789,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,
14790,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)",Revised,8/20/25,Unavailable,Currently not marketed,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,
14791,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)",Revised,8/20/25,Unavailable,Currently not marketed,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,
14792,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)",Revised,8/20/25,Unavailable,Currently not marketed,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,
14793,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)",Revised,8/20/25,Unavailable,Currently not marketed,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,
14794,Methylprednisolone Acetate Injection,Eugia US LLC,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Rheumatology,Current,,
14795,Methylprednisolone Acetate Injection,Eugia US LLC,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Rheumatology,Current,,
14796,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)",Reverified,8/26/25,Available,,,,Rheumatology,Current,,
14797,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)",Reverified,8/26/25,Available,,,,Rheumatology,Current,,
14798,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)",Reverified,8/26/25,Available,,,,Rheumatology,Current,,
14799,Methylprednisolone Acetate Injection,"Par Pharmaceutical, Inc.","Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)",Reverified,9/2/25,Available,,,,Rheumatology,Current,,
14800,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)",Reverified,6/27/25,Available,,,,Rheumatology,Current,,
14801,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)",Reverified,6/27/25,Available,,,,Rheumatology,Current,,
14802,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)",Reverified,6/27/25,Available,,,,Rheumatology,Current,,
14803,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)",Reverified,6/27/25,Available,,,,Rheumatology,Current,,
14804,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)",Reverified,8/15/25,Available,,,,Rheumatology,Current,,
14805,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Rheumatology,Current,,
14806,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)",Revised,8/15/25,Available,,,,Rheumatology,Current,,
14807,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)",Revised,8/15/25,Unavailable,Next Delivery: August 2025; Estimated Recovery: September 2025,,Demand increase for the drug,Rheumatology,Current,,
14808,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)",Reverified,8/15/25,Available,,,,Rheumatology,Current,,
14809,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)",Reverified,8/15/25,Available,,,,Rheumatology,Current,,
14810,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)",Revised,8/15/25,Unavailable,Next Delivery: October 2025; Estimated Recovery: March 2026,,Demand increase for the drug,Rheumatology,Current,,
14811,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)",Reverified,8/15/25,Available,,,,Rheumatology,Current,,
14812,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)",Revised,8/15/25,Unavailable,Next Delivery and Estimated Recovery: September 2025,,Demand increase for the drug,Rheumatology,Current,,
14813,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)",Reverified,8/15/25,Available,,,,Rheumatology,Current,,
14814,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)",Revised,8/15/25,Available,,,,Rheumatology,Current,,
14815,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)",Revised,8/15/25,Available,,,,Rheumatology,Current,,
14816,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)",Revised,8/15/25,Unavailable,Next Delivery: September 2025; Estimated Recovery: June 2026,,Demand increase for the drug,Rheumatology,Current,,
14817,Methylprednisolone Sodium Succinate Injection,Pfizer Inc.,"Solu-Medrol, Injection, 1 g/1 mL (NDC 0009-0698-02)",New,10/10/24,,,,,Rheumatology,To Be Discontinued,,10/10/24
14818,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 25 mg (NDC 65862-062-01)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25
14819,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 25 mg (NDC 65862-062-99)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25
14820,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-01)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25
14821,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-59)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25
14822,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-99)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25
14823,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-01)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25
14824,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-39)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25
14825,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-99)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25
14826,Metronidazole Injection,InfoRLife SA,"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)",Reverified,8/26/25,Limited Availability,Labeler: Hospira Inc.,,Other,Anti-Infective,Current,,
14827,Metronidazole Injection,InfoRLife SA,"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)",Reverified,8/26/25,Available,Labeler: Sagent Pharmaceuticals,,,Anti-Infective,Current,,
14828,Metronidazole Injection,B. Braun Medical Inc.,"Metro I.v. In Plastic Container, Injection, 500 mg/100 mL (NDC 0264-5535-32)",Reverified,8/21/25,Limited Availability,Temporary discontinuation of the manufacture of the drug. Some lots are available through exhaustion of inventory,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,
14829,Metronidazole Injection,Baxter Healthcare,"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)",Reverified,9/3/25,Available,,,,Anti-Infective,Current,,
14830,Metronidazole Injection,Gland Pharma Limited,"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)",Reverified,7/28/25,Unavailable,,,Shortage of an active ingredient,Anti-Infective,Current,,
14831,Midazolam Hydrochloride Injection,WG Critical Care,"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)",Reverified,7/16/25,Available,Please check wholesalers and distributors for inventory.,,,Anesthesia; Neurology,Current,,
14832,Midazolam Hydrochloride Injection,WG Critical Care,"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)",Reverified,7/16/25,Available,Please check wholesalers and distributors for inventory.,,,Anesthesia; Neurology,Current,,
14833,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)",Reverified,9/3/25,Available,,,,Anesthesia; Neurology,Current,,
14834,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)",Reverified,9/3/25,Available,,,,Anesthesia; Neurology,Current,,
14835,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)",Reverified,9/3/25,Available,,,,Anesthesia; Neurology,Current,,
14836,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)",Reverified,9/2/25,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia; Neurology,Current,,
14837,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,
14838,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,
14839,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,
14840,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,
14841,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)",Reverified,9/2/25,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia; Neurology,Current,,
14842,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,
14843,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,
14844,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,
14845,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,
14846,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,
14847,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,
14848,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology,Current,,
14849,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Demand increase for the drug,Anesthesia; Neurology,Current,,
14850,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology,Current,,
14851,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology,Current,,
14852,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology,Current,,
14853,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)",Revised,8/15/25,Unavailable,Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Anesthesia; Neurology,Current,,
14854,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology,Current,,
14855,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 70860-601-10)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,
14856,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 70860-601-05)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,
14857,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 47781-589-17)",Reverified,7/28/25,Unavailable,Alvogen,,Demand increase for the drug,Anesthesia; Neurology,Current,,
14858,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 47781-589-91)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,
14859,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 2 mg/2 mL (NDC 70860-600-02)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,
14860,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 2 mg/2 mL (NDC 47781-588-68)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,
14861,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 2.5 mg (NDC 0245-0211-01)",New,4/28/25,,,,,Cardiovascular,To Be Discontinued,,4/28/25
14862,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 2.5 mg (NDC 0245-0211-11)",New,4/28/25,,,,,Cardiovascular,To Be Discontinued,,4/28/25
14863,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 5 mg (NDC 0245-0212-01)",New,4/28/25,,,,,Cardiovascular,To Be Discontinued,,4/28/25
14864,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 5 mg (NDC 0245-0212-11)",New,4/28/25,,,,,Cardiovascular,To Be Discontinued,,4/28/25
14865,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 10 mg (NDC 0245-0213-01)",New,4/28/25,,,,,Cardiovascular,To Be Discontinued,,4/28/25
14866,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 10 mg (NDC 0245-0213-11)",New,4/28/25,,,,,Cardiovascular,To Be Discontinued,,4/28/25
14867,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 5 mg (NDC 55154-5623-0)",New,4/28/25,,,,,Cardiovascular,To Be Discontinued,,4/28/25
14868,Minocycline Hydrochloride Capsule,"Teva Pharmaceuticals USA, Inc.","Minocycline Hydrochloride, Capsule, 75 mg (NDC 0591-3153-01)",New,5/23/25,,Permanent discontinuation of manufacture due to business decision.,,,Anti-Infective,To Be Discontinued,,5/23/25
14869,Minocycline Hydrochloride Tablet,Strides Pharma Inc.,"Minocycline Hydrochloride, Tablet, 50 mg (NDC 64380-154-01)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Antiviral,To Be Discontinued,,1/22/25
14870,Minocycline Hydrochloride Tablet,Strides Pharma Inc.,"Minocycline Hydrochloride, Tablet, 75 mg (NDC 64380-155-01)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Antiviral,To Be Discontinued,,1/22/25
14871,Minocycline Hydrochloride Tablet,Strides Pharma Inc.,"Minocycline Hydrochloride, Tablet, 100 mg (NDC 64380-156-01)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Antiviral,To Be Discontinued,,1/22/25
14872,Mitomycin Injection,Accord Healthcare Inc.,"Mitomycin, Injection, 20 mg/40 mL (NDC 16729-108-11)",New,1/17/25,,Permanent discontinuation in the manufacturing of the drug.,,,Anti-Infective,To Be Discontinued,,1/17/25
14873,Montelukast Sodium Granule,Organon,"Singulair, Granule, 4 mg (NDC 78206-171-01)",New,3/24/25,,,,,Pulmonary/Allergy,To Be Discontinued,,3/24/25
14874,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0409-1891-23)",New,7/8/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,7/8/25
14875,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0409-1892-01)",New,7/8/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,7/8/25
14876,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0409-1893-01)",New,7/8/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,7/8/25
14877,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)",Revised,9/2/25,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,
14878,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,
14879,Morphine Sulfate Injection,"Amphastar Pharmaceuticals, Inc.","Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)",Reverified,8/19/25,Available,,,,Analgesia/Addiction,Current,,
14880,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)",Reverified,9/2/25,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Demand increase for the drug,Analgesia/Addiction,Current,,
14881,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)",Revised,9/2/25,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,
14882,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)",Reverified,9/2/25,Unavailable,Not available at this time.,,Demand increase for the drug,Analgesia/Addiction,Current,,
14883,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,
14884,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Duramorph (Morphine Sulfate Injection, USP), Injection, 1 mg/1 mL (NDC 0641-6019-10)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Analgesia/Addiction,Current,,
14885,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Duramorph (Morphine Sulfate Injection, USP), Injection, .5 mg/1 mL (NDC 0641-6020-10)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,
14886,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,
14887,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,
14888,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)",Revised,8/15/25,Unavailable,Next Delivery: September 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,,
14889,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)",Revised,8/15/25,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,,
14890,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)",Revised,8/15/25,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,1/3/25,
14891,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)",Reverified,8/15/25,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,
14892,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,,
14893,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/3/25,
14894,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/3/25,
14895,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/3/25,
14896,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,
14897,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)",Reverified,7/23/25,Unavailable,Additional lots will be available in the May 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,
14898,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,
14899,Morphine Sulfate Injection,Piramal Critical Care Inc.,"Mitigo (Morphine Sulfate Injection, USP), Injection, 200 mg/20 mL (NDC 66794-160-02)",Reverified,8/19/25,Limited Availability,On allocation,,Demand increase for the drug,Analgesia/Addiction,Current,,
14900,Morphine Sulfate Injection,Piramal Critical Care Inc.,"Mitigo (Morphine Sulfate Injection, USP), Injection, 500 mg/20 mL (NDC 66794-162-02)",Reverified,8/19/25,Limited Availability,On allocation,,Demand increase for the drug,Analgesia/Addiction,Current,,
14901,Naltrexone Hydrochloride Tablet,Accord Healthcare Inc.,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 16729-081-01)",Reverified,8/19/25,Available,,,,Analgesia/Addiction,Current,,
14902,Naltrexone Hydrochloride Tablet,Accord Healthcare Inc.,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 16729-081-10)",Reverified,8/19/25,Available,,,,Analgesia/Addiction,Current,,
14903,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 51224-206-50)",Reverified,9/2/25,Available,Marketed by Tagi Pharma,,,Analgesia/Addiction,Current,,
14904,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 51224-206-30)",Reverified,9/2/25,Available,Marketed by Tagi Pharma,,,Analgesia/Addiction,Current,,
14905,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 68094-909-50)",Reverified,9/2/25,Available,Marketed by Precision Dose,,,Analgesia/Addiction,Current,,
14906,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 68094-909-30)",Reverified,9/2/25,Available,Marketed by Precision Dose,,,Analgesia/Addiction,Current,,
14907,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Analgesia/Addiction,Current,,
14908,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-83)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Analgesia/Addiction,Current,,
14909,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-08)",Revised,8/20/25,Unavailable,Currently not marketed,,Other,Analgesia/Addiction,Current,,
14910,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-18)",Revised,8/20/25,Unavailable,Currently not marketed,,Other,Analgesia/Addiction,Current,,
14911,Naltrexone Hydrochloride Tablet,SpecGx LLC,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 0406-1170-01)",Revised,9/2/25,Limited Availability,Long term allocations to all customers with intermittent backorder expected through 2025.,,Demand increase for the drug,Analgesia/Addiction,Current,,
14912,Naltrexone Hydrochloride Tablet,SpecGx LLC,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 0406-1170-03)",Revised,9/2/25,Available,Long term allocations to all customers with intermittent backorder expected through 2025.,,Demand increase for the drug,Analgesia/Addiction,Current,,
14913,Naltrexone Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 62135-242-60)",Reverified,8/19/25,Available,,,,Analgesia/Addiction,Current,,
14914,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin in Dextrose 5%, Injection, 20 mg/100 mL (NDC 0338-1049-02)",Revised,9/3/25,Unavailable,Manufacturing delay; Recovery in October 2025,,Other,Cardiovascular,Current,,
14915,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin in Dextrose 5%, Injection, 40 mg/100 mL (NDC 0338-1051-02)",Revised,9/3/25,Unavailable,Manufacturing delay; Recovery in September 2025,,Other,Cardiovascular,Current,,
14916,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin in Dextrose 5%, Injection, 10 mg/100 mL (NDC 0338-1047-02)",Reverified,9/3/25,Unavailable,Manufacturing delay; Recovery in October 2025,,Other,Cardiovascular,Current,,
14917,Nitroglycerin Injection,"American Regent, Inc.","Nitroglycerin, Injection, 5 mg/1 mL (NDC 0517-4810-25)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,
14918,Norepinephrine Bitartrate Injection,"Sun Pharmaceutical Industries, Inc.","Injection, 1 mg/1 mL (NDC 47335-615-44)",New,9/20/24,,,,,Cardiovascular,To Be Discontinued,,9/20/24
14919,Nortriptyline Hydrochloride Capsule,"Teva Pharmaceuticals USA, Inc.","Nortriptyline Hydrochloride, Capsule, 75 mg (NDC 0093-0813-05)",New,5/23/25,,Permanent discontinuation of specific package size/ SKU for business reasons.,,,Psychiatry,To Be Discontinued,,5/23/25
14920,Nystatin Topical Powder,"Upsher-Smith Laboratories, LLC","Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-15)",New,4/28/25,,,,,Anti-Infective; Dermatology,To Be Discontinued,,4/28/25
14921,Nystatin Topical Powder,"Upsher-Smith Laboratories, LLC","Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-30)",New,4/28/25,,,,,Anti-Infective; Dermatology,To Be Discontinued,,4/28/25
14922,Nystatin Topical Powder,"Upsher-Smith Laboratories, LLC","Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-60)",New,4/28/25,,,,,Anti-Infective; Dermatology,To Be Discontinued,,4/28/25
14923,Ondansetron Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 4 mg (NDC 45963-538-30)",New,11/4/24,,,,,Gastroenterology,To Be Discontinued,,11/4/24
14924,Ondansetron Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 8 mg (NDC 45963-539-30)",New,11/4/24,,,,,Gastroenterology,To Be Discontinued,,11/4/24
14925,Oseltamivir Phosphate Capsule,"Genentech, Inc","Tamiflu, Capsule, 30 mg (NDC 0004-0802-85)",New,7/8/25,,Discontinuation of the manufacture of the drug,,,Antiviral,To Be Discontinued,,7/8/25
14926,Oxaliplatin Injection,Novast Labs,"Oxaliplatin, Injection, 50 mg/10 mL (NDC 50742-405-10)",New,4/22/25,,This product is distributed by Ingenus Pharmaceuticals. Customer service: customerservice@ingenus.com or 866-321-5031,,,Oncology,To Be Discontinued,,4/22/25
14927,Oxaliplatin Injection,Novast Labs,"Oxaliplatin, Injection, 100 mg/20 mL (NDC 50742-406-20)",New,4/22/25,,This product is distributed by Ingenus Pharmaceuticals. Customer service: customerservice@ingenus.com or 866-321-5031,,,Oncology,To Be Discontinued,,4/22/25
14928,Oxaliplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 50 mg/10 mL (NDC 0703-3985-01)",New,10/11/24,,A business decision was made to discontinue this product.,,,Oncology,To Be Discontinued,,10/11/24
14929,Oxaliplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 100 mg/20 mL (NDC 0703-3986-01)",New,10/11/24,,A business decision was made to discontinue this product.,,,Oncology,To Be Discontinued,,10/11/24
14930,Oxaliplatin Injection,Sandoz Inc.,"Injection, 5 mg/1 mL (NDC 0781-9315-70)",New,10/16/24,,A business decision was made to discontinue this product.,,,Oncology,To Be Discontinued,,10/16/24
14931,Oxaliplatin Injection,Sandoz Inc.,"Injection, 5 mg/1 mL (NDC 0781-9317-80)",New,10/16/24,,A business decision was made to discontinue this product.,,,Oncology,To Be Discontinued,,10/16/24
14932,Oxaprozin Tablet,"Hospira, Inc., a Pfizer Company","Daypro, Tablet, 600 mg (NDC 0025-1381-31)",New,7/17/25,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction,To Be Discontinued,,7/17/25
14933,Oxazepam Capsule,"Teva Pharmaceuticals USA, Inc.","Oxazepam, Capsule, 10 mg (NDC 0228-2067-10)",Revised,7/3/25,,,Available,,Neurology; Psychiatry,Resolved,7/3/25,
14934,Oxazepam Capsule,"Teva Pharmaceuticals USA, Inc.","Oxazepam, Capsule, 15 mg (NDC 0228-2069-10)",Revised,7/3/25,,,Available,,Neurology; Psychiatry,Resolved,7/3/25,
14935,Oxazepam Capsule,"Teva Pharmaceuticals USA, Inc.","Oxazepam, Capsule, 30 mg (NDC 0228-2073-10)",Revised,7/3/25,,,Available,,Neurology; Psychiatry,Resolved,7/3/25,
14936,Oxybutynin Chloride Tablet,"Upsher-Smith Laboratories, LLC","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-00)",New,5/14/25,,,,,Renal,To Be Discontinued,,5/14/25
14937,Oxybutynin Chloride Tablet,"Upsher-Smith Laboratories, LLC","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-01)",New,5/14/25,,,,,Renal,To Be Discontinued,,5/14/25
14938,Oxybutynin Chloride Tablet,"Upsher-Smith Laboratories, LLC","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-10)",New,5/14/25,,,,,Renal,To Be Discontinued,,5/14/25
14939,Oxybutynin Chloride Tablet,"Upsher-Smith Laboratories, LLC","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-50)",New,5/14/25,,,,,Renal,To Be Discontinued,,5/14/25
14940,Palivizumab Injection,Swedish Orphan Biovitrum AB,"Synagis, Injection, 50 mg/.5 mL (NDC 66658-230-01)",New,8/13/25,,Discontinuation of the manufacture of the drug,,,Antiviral,To Be Discontinued,,8/13/25
14941,Palivizumab Injection,Swedish Orphan Biovitrum AB,"Synagis, Injection, 100 mg/1 mL (NDC 66658-231-01)",New,8/13/25,,Discontinuation of the manufacture of the drug,,,Antiviral,To Be Discontinued,,8/13/25
14942,Pantoprazole Sodium Injection,Sun Pharmaceutical Industries Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-40)",New,12/5/24,,Discontinuing for business reasons,,,Gastroenterology,To Be Discontinued,,12/5/24
14943,Pantoprazole Sodium Injection,Sun Pharmaceutical Industries Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-44)",New,12/5/24,,Discontinuing for business reasons,,,Gastroenterology,To Be Discontinued,,12/5/24
14944,Pantoprazole Sodium Injection,Sun Pharmaceutical Industries Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-45)",New,12/5/24,,Discontinuing for business reasons,,,Gastroenterology,To Be Discontinued,,12/5/24
14945,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 50 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0203-2)",Reverified,8/15/25,Limited Availability,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,
14946,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 75 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0204-2)",Reverified,8/15/25,Limited Availability,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,
14947,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 100 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0205-2)",Reverified,8/15/25,Unavailable,The 100 Mcg Cartridge Is No Longer Available And Takeda Is Unable To Resupply Prior To Ceasing Of Manufacturing Of Natpara At The End Of 2024.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,
14948,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 25 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0202-2)",Reverified,8/15/25,Limited Availability,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,
14949,Peginterferon alfa-2a Injection,pharmaand GmbH (pharma&),"Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1)",Revised,8/19/25,Limited Availability,"Pegasys availability will become more limited through Q4 2025. Product replenishment is expected sometime in 2026 and before May 31, 2026.",,Shortage of an active ingredient,Antiviral,Current,,
14950,Peginterferon alfa-2a Injection,pharmaand GmbH (pharma&),"Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4)",Revised,8/19/25,Limited Availability,"Pegasys availability will become more limited through Q4 2025. Product replenishment is expected sometime in 2026 and before May 31, 2026.",,Shortage of an active ingredient,Antiviral,Current,,
14951,Pemetrexed Ditromethamine Injection,Pfizer Inc.,"Pemetrexed Ditromethamine, Injection, 100 mg Single Dose Vial (NDC 0409-1060-01)",New,7/17/25,,Discontinuation of the manufacture of the drug.,,,Oncology,To Be Discontinued,,7/17/25
14952,Pemetrexed Ditromethamine Injection,Pfizer Inc.,"Pemetrexed Ditromethamine, Injection, 500 mg Single Dose Vial (NDC 0409-1061-01)",New,7/17/25,,Discontinuation of the manufacture of the drug.,,,Oncology,To Be Discontinued,,7/17/25
14953,Penicillin G Benzathine Injection,Laboratorios Atral,"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)",Reverified,7/18/25,Available,,,,Anti-Infective,Current,,
14954,Penicillin G Benzathine Injection,Laboratoires Delbert,"Extencilline, Injection, 1,200,000 units (NDC 81284-521-01)",Reverified,7/18/25,Available,,,,Anti-Infective,Current,,
14955,Penicillin G Benzathine Injection,Laboratoires Delbert,"Extencilline, Injection, 2,400,000 units (NDC 81284-522-01)",Reverified,7/18/25,Available,,,,Anti-Infective,Current,,
14956,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)",Revised,8/25/25,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Anti-Infective,Current,,
14957,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)",Revised,8/25/25,Limited Availability,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,
14958,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)",Revised,8/25/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,
14959,Peritoneal Dialysis Solution,Baxter Healthcare,"Peritoneal Dialysis, Solution, Various NDCs (NDC 0941-0679-05)",Revised,7/7/25,,,Available,,Renal,Resolved,7/7/25,
14960,Peritoneal Dialysis Solution,Fresenius Medical Care North America,"Peritoneal Dialysis, Solution, Various NDCs (NDC 46163-206-94)",Revised,7/7/25,,,Available,,Renal,Resolved,7/7/25,
14961,Phentermine Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Adipex-P, Tablet, 37.5 mg (NDC 57844-140-01)",New,6/13/25,,,,,Other,To Be Discontinued,,6/13/25
14962,Phentermine Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Adipex-P, Tablet, 37.5 mg (NDC 57844-140-56)",New,6/13/25,,,,,Other,To Be Discontinued,,6/13/25
14963,Pimecrolimus Cream,"Bausch Health Americas, Inc.","Elidel, Cream, 30gm (NDC 0187-5100-01)",New,2/28/25,,Authorized generic is still marketed and available under NDC 68682-110-01,,,Dermatology,To Be Discontinued,,2/28/25
14964,Pimecrolimus Cream,"Bausch Health Americas, Inc.","Elidel, Cream, 60gm (NDC 0187-5101-02)",New,2/28/25,,Authorized generics is still marketed and available under NDC 68682-111-02,,,Dermatology,To Be Discontinued,,2/28/25
14965,Pimecrolimus Cream,"Bausch Health Americas, Inc.","Elidel, Cream, 100gm (NDC 0187-5102-03)",New,2/28/25,,Authorized generics is still marketed and available under NDC 68682-112-03,,,Dermatology,To Be Discontinued,,2/28/25
14966,Pirfenidone Capsule,"Genentech, Inc","Esbriet, Capsule, 267 mg (NDC 50242-121-01)",New,2/5/25,,,,,Pulmonary/Allergy,To Be Discontinued,,2/5/25
14967,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 600 mg (NDC 62037-559-01)",New,5/19/25,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/25
14968,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 600 mg (NDC 62037-559-05)",New,5/19/25,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/25
14969,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-01)",New,5/19/25,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/25
14970,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-05)",New,5/19/25,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/25
14971,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-10)",New,5/19/25,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/25
14972,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-90)",New,5/19/25,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/25
14973,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Potassium Chloride, Tablet, Extended Release, 600 mg (NDC 0832-5322-11)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25
14974,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Potassium Chloride, Tablet, Extended Release, 600 mg (NDC 0832-5322-10)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25
14975,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Potassium Chloride, Tablet, Extended Release, 750 mg (NDC 0832-5323-11)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25
14976,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Potassium Chloride, Tablet, Extended Release, 750 mg (NDC 0832-5323-10)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25
14977,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-01)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25
14978,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-11)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25
14979,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-15)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25
14980,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-01)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25
14981,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-15)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25
14982,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-11)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25
14983,"Potassium Citrate Tablet, Extended Release",Watson Pharma Private Limited,"Potassium Citrate, Tablet, Extended Release, 5 meq (NDC 0591-2682-01)",New,7/17/25,,A business decision was made to discontinue.,,,Renal,To Be Discontinued,,7/17/25
14984,"Potassium Citrate Tablet, Extended Release",Watson Pharma Private Limited,"Potassium Citrate, Tablet, Extended Release, 10 meq (NDC 0591-2729-01)",New,7/17/25,,A business decision was made to discontinue.,,,Renal,To Be Discontinued,,7/17/25
14985,"Potassium Citrate Tablet, Extended Release",Watson Pharma Private Limited,"Potassium Citrate, Tablet, Extended Release, 15 meq (NDC 0591-2742-01)",New,7/17/25,,A business decision was made to discontinue.,,,Renal,To Be Discontinued,,7/17/25
14986,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 10 mg (NDC 0093-0771-10)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25
14987,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 10 mg (NDC 0093-0771-98)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25
14988,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 20 mg (NDC 0093-7201-10)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25
14989,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 20 mg (NDC 0093-7201-98)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25
14990,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 40 mg (NDC 0093-7202-10)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25
14991,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 40 mg (NDC 0093-7202-98)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25
14992,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 80 mg (NDC 0480-7270-10)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25
14993,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 80 mg (NDC 0480-7270-98)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25
14994,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 1 mg (NDC 0069-4310-71)",New,4/28/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023,,,Cardiovascular,To Be Discontinued,4/28/23,4/28/23
14995,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 2 mg (NDC 0069-4370-71)",New,4/28/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023,,,Cardiovascular,To Be Discontinued,4/28/23,4/28/23
14996,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 5 mg (NDC 0069-4380-71)",New,4/28/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023,,,Cardiovascular,To Be Discontinued,4/28/23,4/28/23
14997,Promethazine Hydrochloride Injection,"XGen Pharmaceuticals DJB, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)",Reverified,8/4/25,Unavailable,Next lots scheduled for release August 2025.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy,Current,,
14998,Promethazine Hydrochloride Injection,"XGen Pharmaceuticals DJB, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)",Reverified,8/4/25,Available,,,,Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy,Current,,
14999,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)",Revised,7/23/25,Unavailable,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,Other,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,
15000,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)",Revised,7/23/25,Unavailable,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,Other,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,
15001,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)",Revised,7/23/25,Unavailable,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,
15002,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)",Revised,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,
15003,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergen, Injection, 25 mg/1 mL (NDC 0641-6084-25)",Revised,7/23/25,Unavailable,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,Other,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,
15004,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergen, Injection, 50 mg/1 mL (NDC 0641-6085-25)",Revised,7/23/25,Unavailable,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,Other,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,
15005,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6082-25)",Revised,7/23/25,Available,Currently available.  Additional product will be made available as it is released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,
15006,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergen, Injection, 50 mg/1 mL (NDC 0641-6083-25)",Revised,7/23/25,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,
15007,"Propafenone Hydrochloride Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Propafenone Hydrochloride, Capsule, Extended Release, 225 mg (NDC 0832-0740-60)",New,5/14/25,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/25
15008,"Propafenone Hydrochloride Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Propafenone Hydrochloride, Capsule, Extended Release, 325 mg (NDC 0832-0741-60)",New,5/14/25,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/25
15009,"Propafenone Hydrochloride Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Propafenone Hydrochloride, Capsule, Extended Release, 425 mg (NDC 0832-0742-60)",New,5/14/25,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/25
15010,Propranolol Hydrochloride Injection,"Fresenius Kabi USA, LLC","Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,
15011,Propranolol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)",Reverified,7/23/25,Unavailable,,,Shortage of an active ingredient,Cardiovascular,Current,,
15012,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,
15013,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,
15014,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,
15015,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,
15016,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)",Reverified,6/27/25,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,Shortage of an active ingredient,Cardiovascular,Current,,
15017,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)",Reverified,6/27/25,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,Shortage of an active ingredient,Cardiovascular,Current,,
15018,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)",Reverified,6/27/25,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,Shortage of an active ingredient,Cardiovascular,Current,,
15019,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)",Reverified,6/27/25,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,Shortage of an active ingredient,Cardiovascular,Current,,
15020,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)",Reverified,8/19/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,
15021,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)",Reverified,8/19/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,
15022,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)",Reverified,8/19/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,
15023,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)",Reverified,8/19/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,
15024,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)",Reverified,6/25/25,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,
15025,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)",Reverified,6/25/25,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,
15026,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)",Reverified,6/25/25,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,
15027,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)",Reverified,6/25/25,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,
15028,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 40 mg (NDC 0071-0535-23)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,
15029,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 10 mg (NDC 0071-0530-23)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,
15030,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 20 mg (NDC 0071-0532-23)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,
15031,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 5 mg (NDC 0071-0527-23)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,
15032,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,
15033,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,
15034,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,
15035,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)",Reverified,6/25/25,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,
15036,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)",Reverified,6/25/25,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,
15037,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)",Reverified,6/25/25,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,
15038,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings LLC,"Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,
15039,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings LLC,"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,
15040,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings LLC,"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,
15041,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 43598-741-01)",New,1/8/25,,,,,Other,To Be Discontinued,,1/8/25
15042,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 43598-741-10)",New,1/8/25,,,,,Other,To Be Discontinued,,1/8/25
15043,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 43598-741-30)",New,1/8/25,,,,,Other,To Be Discontinued,,1/8/25
15044,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 50268-708-15)",New,1/8/25,,,,,Other,To Be Discontinued,,1/8/25
15045,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 72162-2169-3)",New,1/8/25,,,,,Other,To Be Discontinued,,1/8/25
15046,Ramipril Capsule,Pfizer Inc.,"Altace, Capsule, 2.5 mg (NDC 61570-111-01)",New,1/30/25,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To Be Discontinued,,1/30/25
15047,Ramipril Capsule,Pfizer Inc.,"Altace, Capsule, 10 mg (NDC 61570-120-01)",New,1/30/25,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To Be Discontinued,,1/30/25
15048,"Ranolazine Granules, Extended Release","Sun Pharmaceutical Industries, Inc.","Aspruzyo Sprinkle, Granules, Extended Release, 500 mg (NDC 47335-624-60)",New,9/20/24,,,,,Cardiovascular,To Be Discontinued,,9/20/24
15049,"Ranolazine Granules, Extended Release","Sun Pharmaceutical Industries, Inc.","Aspruzyo Sprinkle, Granules, Extended Release, 1000 mg (NDC 47335-625-60)",New,9/20/24,,,,,Cardiovascular,To Be Discontinued,,9/20/24
15050,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 2 mg (NDC 72078-035-02)",Reverified,9/3/25,Available,,,,Analgesia/Addiction,Current,,
15051,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 5 mg (NDC 72078-036-05)",Reverified,9/3/25,Available,,,,Analgesia/Addiction,Current,,
15052,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)",Reverified,7/23/25,Unavailable,,,Demand increase for the drug,Analgesia/Addiction,Current,,
15053,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)",Reverified,7/23/25,Unavailable,,,Demand increase for the drug,Analgesia/Addiction,Current,,
15054,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)",Reverified,7/23/25,Unavailable,,,Demand increase for the drug,Analgesia/Addiction,Current,,
15055,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,
15056,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,
15057,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,
15058,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)",Reverified,9/3/25,Available,,,,Analgesia/Addiction,Current,,
15059,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 150 mg (NDC 42806-801-30)",Reverified,9/2/25,Available,,,,Anti-Infective,Current,,
15060,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 150 mg (NDC 42806-801-01)",Reverified,9/2/25,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,
15061,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 300 mg (NDC 42806-799-30)",Reverified,9/2/25,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,
15062,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 300 mg (NDC 42806-799-60)",Reverified,9/2/25,Available,,,,Anti-Infective,Current,,
15063,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 300 mg (NDC 42806-799-01)",Reverified,9/2/25,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,
15064,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 300 mg (NDC 42806-799-05)",Reverified,9/2/25,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,
15065,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 150 mg (NDC 68180-658-06)",Reverified,8/19/25,Available,,,,Anti-Infective,Current,,
15066,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 300 mg (NDC 68180-659-06)",Reverified,8/19/25,Available,,,,Anti-Infective,Current,,
15067,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 300 mg (NDC 68180-659-07)",Reverified,8/19/25,Available,,,,Anti-Infective,Current,,
15068,Rifampin Injection,"Fresenius Kabi USA, LLC","Rifampin, Injection, 600 mg (NDC 63323-351-20)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anti-Infective,Current,,
15069,Rifampin Injection,Sanofi-Aventis U.S. LLC,"Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)",Reverified,6/27/25,Available,,,,Anti-Infective,Current,,
15070,Rifampin Injection,"Mylan Institutional, a Viatris Company","Rifampin, Injection, 600 mg/10 mL (NDC 67457-445-60)",Reverified,9/3/25,Available,,,,Anti-Infective,Current,,
15071,"Rifapentine Tablet, Film Coated",Sanofi-Aventis U.S. LLC,"Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24)",Reverified,6/27/25,Available,,,,Anti-Infective,Current,,
15072,Riluzole Oral Suspension,"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)",Reverified,9/2/25,Available,,,,Neurology,Current,,
15073,Riluzole Oral Suspension,"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)",Reverified,9/2/25,Available,,,,Neurology,Current,,
15074,Riluzole Oral Suspension,"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)","Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-2)",Reverified,9/2/25,Unavailable,Next release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to viscosity testing,,Requirements related to complying with good manufacturing practices,Neurology,Current,,
15075,Riluzole Oral Suspension,"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)",Reverified,9/2/25,Available,,,,Neurology,Current,,
15076,Rocuronium Bromide Injection,Piramal Critical Care Inc.,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)",Reverified,8/19/25,Limited Availability,On allocation,,Demand increase for the drug,Anesthesia,Current,,
15077,Rocuronium Bromide Injection,Piramal Critical Care Inc.,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,
15078,Rocuronium Bromide Injection,"Meitheal Pharmaceuticals, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,
15079,Rocuronium Bromide Injection,"Meitheal Pharmaceuticals, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,
15080,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesaler for inventory.,,Delay in shipping of the drug,Anesthesia,Current,,
15081,Rocuronium Bromide Injection,Eugia US LLC,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,
15082,Rocuronium Bromide Injection,Eugia US LLC,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
15083,Rocuronium Bromide Injection,"Mylan Institutional, a Viatris Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,
15084,Rocuronium Bromide Injection,Baxter Healthcare,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,
15085,Rocuronium Bromide Injection,Baxter Healthcare,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,
15086,Rocuronium Bromide Injection,"Hikma Pharmaceuticals USA, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)",Reverified,7/23/25,Available,Additional lots will be available.  Product will be made available as it is released.,,,Anesthesia,Current,,
15087,Rocuronium Bromide Injection,"Hikma Pharmaceuticals USA, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)",Reverified,7/23/25,Available,,,,Anesthesia,Current,,
15088,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
15089,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)",Reverified,9/2/25,Unavailable,Backordered. Next release October 2025. Check wholesaers for inventory.,,Delay in shipping of the drug,Anesthesia,Current,,
15090,Rocuronium Bromide Injection,"XGen Pharmaceuticals DJB, Inc.","Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)",Reverified,9/4/25,Available,Tamarang is the application holder and X-Gen is the distributor/labeler,,,Anesthesia,Current,,
15091,Rocuronium Bromide Injection,"XGen Pharmaceuticals DJB, Inc.","Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)",Reverified,9/4/25,Available,Tamarang is the application holder and X-Gen is the distributor/labeler,,,Anesthesia,Current,,
15092,Rocuronium Bromide Injection,Sagent Pharmaceuticals,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)",Reverified,8/26/25,Available,,,,Anesthesia,Current,,
15093,Rocuronium Bromide Injection,"Mylan Institutional, a Viatris Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,
15094,Rocuronium Bromide Injection,Sandoz Inc.,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
15095,Rocuronium Bromide Injection,Sandoz Inc.,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
15096,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
15097,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
15098,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
15099,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,
15100,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)",Reverified,8/26/25,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,
15101,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)",Reverified,8/26/25,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,
15102,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,
15103,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,
15104,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,
15105,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,
15106,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,
15107,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,
15108,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,
15109,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)",Reverified,8/26/25,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,
15110,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)",Reverified,8/26/25,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,
15111,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)",Reverified,8/26/25,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,
15112,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)",Reverified,8/26/25,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,
15113,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)",Reverified,9/2/25,Limited Availability,Check wholesalers for inventory; Marketed by Baxter,,Other,Anesthesia,Current,,
15114,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)",Reverified,9/2/25,Available,Check wholesalers for inventory; Marketed by Baxter,,,Anesthesia,Current,,
15115,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)",Reverified,9/2/25,Limited Availability,Limited supply; Check wholesalers for inventory; Marketed by Baxter,,Other,Anesthesia,Current,,
15116,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)",Reverified,9/2/25,Available,Check wholesalers for inventory; Marketed by Baxter,,,Anesthesia,Current,,
15117,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
15118,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,
15119,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
15120,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
15121,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,
15122,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,
15123,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
15124,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)",Revised,9/3/25,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,
15125,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)",Revised,9/3/25,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,
15126,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)",Revised,9/3/25,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,
15127,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)",Revised,9/3/25,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia,Current,,
15128,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)",Revised,9/3/25,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,
15129,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)",Revised,9/3/25,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,
15130,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)",Revised,9/3/25,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,
15131,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)",Revised,9/3/25,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,
15132,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)",Revised,9/3/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,
15133,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)",Revised,9/3/25,Available,,,,Anesthesia,Current,,
15134,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)",Revised,9/3/25,Available,,,,Anesthesia,Current,,
15135,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)",Revised,9/3/25,Available,,,,Anesthesia,Current,,
15136,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)",Revised,9/3/25,Available,,,,Anesthesia,Current,,
15137,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)",Revised,9/3/25,Available,,,,Anesthesia,Current,,
15138,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)",Revised,9/3/25,Available,,,,Anesthesia,Current,,
15139,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)",Revised,9/3/25,Available,,,,Anesthesia,Current,,
15140,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)",Revised,9/3/25,Available,,,,Anesthesia,Current,,
15141,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)",Revised,9/3/25,Available,,,,Anesthesia,Current,,
15142,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)",Revised,9/3/25,Available,,,,Anesthesia,Current,,
15143,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)",Revised,9/3/25,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,
15144,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)",Revised,9/3/25,Available,,,,Anesthesia,Current,,
15145,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)",Revised,9/3/25,Available,,,,Anesthesia,Current,,
15146,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-01)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25
15147,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-03)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25
15148,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-05)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25
15149,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-01)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25
15150,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-03)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25
15151,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-05)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25
15152,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-01)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25
15153,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-03)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25
15154,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-05)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25
15155,Silodosin Capsule,AbbVie Inc.,"Rapaflo, Capsule, 4 mg (NDC 0023-6147-30)",New,2/20/25,,Last lot in distribution expires March 2026. Last sale date will be June 2025.,,,Urology,To Be Discontinued,,2/20/25
15156,Silodosin Capsule,AbbVie Inc.,"Rapaflo, Capsule, 8 mg (NDC 0023-6142-30)",New,2/20/25,,Last lot in distribution expires March 2026. Last sale date will be June 2025.,,,Urology,To Be Discontinued,,2/20/25
15157,Silver Nitrate Solution,"Teva Pharmaceuticals USA, Inc.","Solution, .005 g/1 mL (NDC 0093-9614-13)",New,10/15/24,,,,,Dermatology,To Be Discontinued,,10/15/24
15158,Sodium Acetate Injection,"Fresenius Kabi USA, LLC","Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Total Parenteral Nutrition,Current,,
15159,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,
15160,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,
15161,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,
15162,Sodium Acetate Injection,Milla Pharmaceuticals,"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)",Reverified,9/2/25,Available,,,,Total Parenteral Nutrition,Current,,
15163,Sodium Acetate Injection,Milla Pharmaceuticals,"Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)",Reverified,9/2/25,Available,,,,Total Parenteral Nutrition,Current,,
15164,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,
15165,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,
15166,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,
15167,Sodium Acetate Injection,Milla Pharmaceuticals,"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 69784-232-01)",Reverified,9/2/25,Limited Availability,Limited Availability,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,
15168,Sodium Acetate Injection,Milla Pharmaceuticals,"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 69784-229-10)",Reverified,9/2/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,
15169,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)",Revised,9/2/25,Available,Next batch release expected in 2 weeks.,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,
15170,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)",Reverified,9/2/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,
15171,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: September 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/25,
15172,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/25,
15173,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/25,
15174,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,
15175,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)",Revised,8/15/25,Unavailable,Next Delivery and Estimated Recovery: March 2026,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/25,
15176,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)",Revised,8/15/25,Unavailable,Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/25,
15177,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)",Revised,8/15/25,Unavailable,Next Delivery and Estimated Recovery: December 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/25,
15178,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/25,
15179,Sodium Bicarbonate Injection,"Amphastar Pharmaceuticals, Inc.","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)",Reverified,8/19/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,
15180,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,
15181,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)",Reverified,9/2/25,Unavailable,Backordered. Next release October 2025. Check wholesalers for inventory.,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,
15182,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)",Revised,9/2/25,Limited Availability,Over 3 weeks in Channel. Next release 9/8/25,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,
15183,Sodium Bicarbonate Injection,Long Grove Pharmaceuticals LLC,"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)",Reverified,6/27/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,
15184,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-5802-00)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15185,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-5802-10)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15186,Sodium Chloride 0.9% Injection,Fresenius Medical Care North America,"Sodium Chloride 0.9% in Plastic Container, Injection, 900 mg/100 mL (NDC 46163-300-10)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Gastroenterology; Renal,To Be Discontinued,,6/10/25
15187,Sodium Chloride 0.9% Injection,Fresenius Medical Care North America,"Sodium Chloride 0.9% in Plastic Container, Injection, 900 mg/100 mL (NDC 49230-300-10)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Gastroenterology; Renal,To Be Discontinued,,6/10/25
15188,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-02)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15189,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-10)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15190,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-20)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15191,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 63323-186-00)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15192,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-10)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15193,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-12)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15194,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-20)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15195,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-50)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15196,Sodium Chloride 0.9% Injection,"Medefil, Inc.","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 64253-202-30)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15197,Sodium Chloride 0.9% Injection,"Hikma Pharmaceuticals USA, Inc.","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 0641-0497-25)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15198,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9%, Injection, 4 meq/1 mL (NDC 63323-095-61)",Revised,8/8/25,,,Available,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Resolved,8/8/25,
15199,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-13)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15200,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-36)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15201,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-37)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15202,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-23)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15203,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-20)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15204,Sodium Chloride 0.9% Injection,Guerbet LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 mg/1 mL (NDC 0019-1188-81)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15205,Sodium Chloride 0.9% Injection,Guerbet LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 mg/1 mL (NDC 0019-1188-27)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15206,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-924-30)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15207,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-924-10)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15208,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-12)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15209,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-05)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15210,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-07)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15211,Sodium Chloride 0.9% Injection,"Spectra Medical Devices, LLC","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 65282-1510-1)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15212,Sodium Chloride 0.9% Injection,"Spectra Medical Devices, LLC","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 65282-1505-1)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,
15213,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-00)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15214,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-10)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15215,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-20)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15216,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-09)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15217,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-32)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15218,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-31)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15219,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-36)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15220,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-66)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15221,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-67)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15222,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-02)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15223,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-21)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15224,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-31)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15225,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-01)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15226,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-41)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15227,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-11)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15228,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-466-60)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15229,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-468-50)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15230,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-472-20)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15231,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-474-10)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15232,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-18)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15233,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-41)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15234,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-48)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15235,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-31)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15236,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-02)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15237,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-03)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15238,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-04)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15239,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-10)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15240,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-11)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15241,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-38)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15242,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-02)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15243,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-06)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15244,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-04)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15245,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-0553-11)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15246,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 450 mg/100 mL (NDC 0338-9151-30)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15247,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-9159-30)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15248,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-0553-18)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15249,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-02)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15250,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-04)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15251,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-06)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15252,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .45 g/100 mL (NDC 0264-7802-00)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15253,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .45 g/100 mL (NDC 0264-7802-10)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15254,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-03)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15255,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-09)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15256,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 50 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-01)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15257,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 100 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-02)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15258,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 250 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-03)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15259,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 500 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-04)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15260,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 1000 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-05)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15261,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-61)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15262,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-02)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15263,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-55)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,
15264,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-02)",Revised,7/2/25,,,,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,
15265,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-03)",Revised,7/2/25,,,,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,
15266,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-04)",Revised,7/2/25,,,,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,
15267,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-6138-22)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,
15268,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-6138-03)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,
15269,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-7138-09)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,
15270,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-7138-36)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,
15271,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-7388-60)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,
15272,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-7388-50)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,
15273,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-2201-10)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,
15274,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-2201-00)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,
15275,Sodium Chloride 23.4% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride, Injection, 400 mEq/100 mL (4 mEq/mL) (NDC 0409-1141-02)",Revised,7/2/25,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,7/2/25,
15276,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 23.4%, Injection, 4 meq/1 mL (NDC 63323-099-63)",Revised,7/2/25,,,Available,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Resolved,7/2/25,
15277,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 23.4%, Injection, 4 meq/1 mL (NDC 63323-093-30)",Revised,7/2/25,,,Available,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Resolved,7/2/25,
15278,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 5 mg/1.5 mL (NDC 0169-7704-21)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15279,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 10 mg/1.5 mL (NDC 0169-7705-21)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15280,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 15 mg/1.5 mL (NDC 0169-7708-21)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15281,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15282,Somatropin Injection,Sandoz Inc.,"Omnitrope, Injection, 5 mg/1.5 mL (NDC 0781-3001-07)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15283,Somatropin Injection,Sandoz Inc.,"Omnitrope, Injection, 10 mg/1.5 mL (NDC 0781-3004-07)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15284,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, 12 mg/cartridge (NDC 0002-8148-01)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15285,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, 24 mg/cartridge (NDC 0002-8149-01)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15286,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 5 mg/mL, w/ preservative (NDC 0013-2626-81)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15287,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 12 mg/mL, w/ preservative (NDC 0013-2646-81)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15288,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.2 mg preservative free (NDC 0013-2649-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15289,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.4 mg preservative free (NDC 0013-2650-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15290,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.6 mg preservative free (NDC 0013-2651-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15291,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.8 mg preservative free (NDC 0013-2652-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15292,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.0 mg preservative free (NDC 0013-2653-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15293,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.2 mg preservative free (NDC 0013-2654-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15294,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.4 mg preservative free (NDC 0013-2655-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15295,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.6 mg preservative free (NDC 0013-2656-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15296,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.8 mg preservative free (NDC 0013-2657-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15297,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 2.0 mg preservative free (NDC 0013-2658-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,
15298,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, Humatrope Kit 6 mg (0002-8147-01): 1 TRAY in 1 CARTON (0002-8147-01) / 1 KIT in 1 TRAY * 2.88 mL in 1 CARTRIDGE (0002-7554-01) * 2.88 mL in 1 SYRINGE (0002-7618-01) (NDC 0002-8147-01)",New,10/29/24,,Business decision to discontinue. Discontinuation includes the associated HumatroPen injection device.,,,Endocrinology/Metabolism,To Be Discontinued,,10/29/24
15299,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, Humatrope Kit 12 mg (0002-8148-01): 1 TRAY in 1 CARTON (0002-8148-01) / 1 KIT in 1 TRAY * 2.88 mL in 1 CARTRIDGE (0002-7555-01) * 2.88 mL in 1 SYRINGE (0002-7619-01) (NDC 0002-8148-01)",New,10/29/24,,Business decision to discontinue. Discontinuation includes the associated HumatroPen injection device.,,,Endocrinology/Metabolism,To Be Discontinued,,10/29/24
15300,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, Humatrope Kit 24 mg (0002-8149-01): 1 TRAY in 1 CARTON (0002-8149-01) / 1 KIT in 1 TRAY * 2.88 mL in 1 CARTRIDGE (0002-7556-01) * 2.88 mL in 1 SYRINGE (0002-7619-01) (NDC 0002-8149-01)",New,10/29/24,,Business decision to discontinue. Discontinuation includes the associated HumatroPen injection device.,,,Endocrinology/Metabolism,To Be Discontinued,,10/29/24
15301,Sterile Water Injection,"Hikma Pharmaceuticals USA, Inc.","Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)",Reverified,7/23/25,Available,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,,Other,Current,,
15302,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)",Reverified,8/15/25,Available,,,,Other,Current,,
15303,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)",Reverified,8/15/25,Available,,,,Other,Current,,
15304,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)",Reverified,8/15/25,Available,,,,Other,Current,,
15305,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)",Reverified,8/15/25,Available,,,,Other,Current,,
15306,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Other,Current,,
15307,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Other,Current,,
15308,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Other,Current,,
15309,Sterile Water Injection,"Medefil, Inc.","Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)",Reverified,8/15/25,Available,,,,Other,Current,,
15310,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Other,Current,,
15311,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Other,Current,,
15312,Sterile Water Injection,Nephron Pharmaceuticals Corporation,"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)",Reverified,7/2/25,Unavailable,Product can be manufactured as requested,,Other,Other,Current,,
15313,Sterile Water Irrigant,Otsuka ICU Medical LLC,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)",Reverified,8/20/25,Unavailable,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Other,Gastroenterology; Other; Pediatric,Current,,
15314,Sterile Water Irrigant,Otsuka ICU Medical LLC,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)",Reverified,8/20/25,Limited Availability,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Other,Gastroenterology; Other; Pediatric,Current,,
15315,Sterile Water Irrigant,Otsuka ICU Medical LLC,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)",Reverified,8/20/25,Limited Availability,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Other,Gastroenterology; Other; Pediatric,Current,,
15316,Sterile Water Irrigant,Otsuka ICU Medical LLC,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)",Reverified,8/20/25,Limited Availability,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Other,Gastroenterology; Other; Pediatric,Current,,
15317,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)",Reverified,9/3/25,Available,,,,Gastroenterology; Other; Pediatric,Current,,
15318,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)",Reverified,9/3/25,Available,,,,Gastroenterology; Other; Pediatric,Current,,
15319,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)",Reverified,9/3/25,Available,,,,Gastroenterology; Other; Pediatric,Current,,
15320,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)",Reverified,8/21/25,Available,,,,Gastroenterology; Other; Pediatric,Current,,
15321,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)",Reverified,8/21/25,Available,,,,Gastroenterology; Other; Pediatric,Current,,
15322,"Streptozocin Powder, For Solution","ESTEVE PHARMACEUTICALS, S.A.","Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)",Revised,6/30/25,Available,,,,Oncology,Current,,
15323,"Streptozocin Powder, For Solution","Teva Pharmaceuticals USA, Inc.","Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)",Revised,8/19/25,Unavailable,Estimated recovery: TBD,,Other,Oncology,Current,,
15324,Sufentanil Citrate Injection,"Hospira, Inc., a Pfizer Company","Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)",Revised,8/15/25,Available,,,,Analgesia/Addiction; Pediatric,Current,,
15325,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)",Reverified,7/23/25,Unavailable,Not currently manufactured,,Other,Analgesia/Addiction; Pediatric,Current,,
15326,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)",Revised,7/23/25,Unavailable,Not currently manufactured,,Other,Analgesia/Addiction; Pediatric,Current,,
15327,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)",Revised,7/23/25,Unavailable,Not currently manufactured,,Other,Analgesia/Addiction; Pediatric,Current,,
15328,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .25 mg (NDC 0069-0296-30)",New,1/13/25,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0353-30",,,Oncology,To Be Discontinued,,1/13/25
15329,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .1 mg (NDC 0069-1031-30)",New,1/13/25,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0252-30",,,Oncology,To Be Discontinued,,1/13/25
15330,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, 1 mg (NDC 0069-1195-30)",New,1/13/25,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0757-30",,,Oncology,To Be Discontinued,,1/13/25
15331,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .35 mg (NDC 0069-1235-30)",New,1/13/25,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0454-30",,,Oncology,To Be Discontinued,,1/13/25
15332,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .5 mg (NDC 0069-1501-30)",New,1/13/25,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0546-30",,,Oncology,To Be Discontinued,,1/13/25
15333,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .75 mg (NDC 0069-1751-30)",New,1/13/25,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0655-30",,,Oncology,To Be Discontinued,,1/13/25
15334,Tamsulosin Hydrochloride Capsule,Sandoz Inc.,"Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-01)",New,4/10/25,,,,,Urology,To Be Discontinued,,4/10/25
15335,Tamsulosin Hydrochloride Capsule,Sandoz Inc.,"Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-10)",New,4/10/25,,,,,Urology,To Be Discontinued,,4/10/25
15336,Tamsulosin Hydrochloride Capsule,Sandoz Inc.,"Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-92)",New,4/10/25,,,,,Urology,To Be Discontinued,,4/10/25
15337,Tbo-filgrastim Injection,"Cephalon, LLC","Granix, Injection, 480 ug/1.6 mL (NDC 63459-920-59)",New,6/13/25,,,,,Hematology,To Be Discontinued,,6/13/25
15338,Technetium TC-99M Pyrophosphate Kit Injection,Curium US LLC,"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)",Reverified,9/2/25,Unavailable,Unavailable,,Shortage of an active ingredient,Medical Imaging,Current,,
15339,Technetium TC-99M Pyrophosphate Kit Injection,"Sun Pharmaceutical Industries, Inc.","CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)",Revised,8/20/25,Limited Availability,Additional supply anticipated early 2026,,Shortage of an active ingredient,Medical Imaging,Current,,
15340,Technetium TC-99M Pyrophosphate Kit Injection,"Sun Pharmaceutical Industries, Inc.","CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)",Revised,8/20/25,Limited Availability,Additional supply anticipated early 2026,,Shortage of an active ingredient,Medical Imaging,Current,,
15341,Telmisartan Tablet,"Boehringer Ingelheim Pharmaceuticals, Inc.","Micardis, Tablet, 20 mg (NDC 0597-0039-37)",New,10/22/24,,Discontinued for business reasons,,,Cardiovascular,To Be Discontinued,,10/22/24
15342,Telmisartan Tablet,"Boehringer Ingelheim Pharmaceuticals, Inc.","Micardis, Tablet, 40 mg (NDC 0597-0040-37)",New,10/22/24,,Discontinued for business reasons,,,Cardiovascular,To Be Discontinued,,10/22/24
15343,Telmisartan Tablet,"Boehringer Ingelheim Pharmaceuticals, Inc.","Micardis, Tablet, 80 mg (NDC 0597-0041-37)",New,10/22/24,,Discontinued for business reasons,,,Cardiovascular,To Be Discontinued,,10/22/24
15344,Teriflunomide Tablet,Apotex Corp.,"Teriflunomide, Tablet, 7 mg (NDC 60505-4477-3)",New,1/28/25,,,,,Neurology,To Be Discontinued,,1/28/25
15345,Teriflunomide Tablet,Apotex Corp.,"Teriflunomide, Tablet, 14 mg (NDC 60505-4478-3)",New,1/28/25,,,,,Neurology,To Be Discontinued,,1/28/25
15346,Testosterone Cypionate Injection,Pfizer Inc.,"Depo-Testosterone, Injection, 200 mg/1 mL (NDC 0009-0086-10)",New,9/25/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,9/25/24
15347,Testosterone Cypionate Injection,Pfizer Inc.,"Depo-Testosterone, Injection, 200 mg/1 mL (NDC 0409-6562-02)",New,9/25/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,9/25/24
15348,Testosterone Cypionate Injection,Pfizer Inc.,"Depo-Testosterone, Injection, 200 mg/1 mL (NDC 0409-6562-22)",New,9/25/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,9/25/24
15349,"Testosterone Gel; Gel, Metered","Actavis Pharma, Inc.","Testosterone, Gel; Gel, Metered, 16.2 mg/1 g (NDC 0591-2925-30)",New,6/16/25,,Discontinuation of the manufacture of the drug,,,Urology,To Be Discontinued,,6/16/25
15350,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 2 mg (NDC 62756-200-83)",New,12/9/24,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/24
15351,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 2 mg (NDC 62756-200-18)",New,12/9/24,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/5/24
15352,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-83)",New,12/9/24,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/24
15353,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-88)",New,12/9/24,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/24
15354,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-08)",New,12/9/24,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/24
15355,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-18)",New,12/9/24,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/24
15356,Tigecycline Injection,"Fresenius Kabi USA, LLC","Injection, 50 mg/5 mL (NDC 63323-960-10)",New,12/9/24,,Check wholesalers for inventory.,,,Anti-Infective,To Be Discontinued,,12/9/24
15357,Tigecycline Injection,Sandoz Inc.,"Tigecycline, Injection, 50 mg/10 mL (NDC 0781-3481-92)",New,1/17/25,,,,,Anti-Infective,To Be Discontinued,,1/17/25
15358,Tobramycin Solution,"Teva Pharmaceuticals USA, Inc.","Tobramycin, Solution, 300 mg/4 mL (NDC 0093-3750-28)",New,6/16/25,,Discontinuation of the manufacture of the drug,,,Pulmonary/Allergy,To Be Discontinued,,6/16/25
15359,Tobramycin Solution,"Teva Pharmaceuticals USA, Inc.","Tobramycin, Solution, 300 mg/4 mL (NDC 0093-3750-63)",New,6/16/25,,Discontinuation of the manufacture of the drug,,,Pulmonary/Allergy,To Be Discontinued,,6/16/25
15360,Tobramycin Solution,"Teva Pharmaceuticals USA, Inc.","Tobramycin, Solution, 300 mg/5 mL (NDC 0093-4085-63)",New,6/16/25,,Discontinuation of the manufacture of the drug,,,Pulmonary/Allergy,To Be Discontinued,,6/16/25
15361,"Tolterodine Tartrate Capsule, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Detrol LA, Capsule, Extended Release, 2 mg (NDC 58151-103-77)",New,2/26/25,,,,,Urology,To Be Discontinued,,2/26/25
15362,"Tolterodine Tartrate Capsule, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Detrol LA, Capsule, Extended Release, 2 mg (NDC 58151-103-93)",New,2/26/25,,,,,Urology,To Be Discontinued,,2/26/25
15363,"Tolterodine Tartrate Capsule, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Detrol LA, Capsule, Extended Release, 4 mg (NDC 58151-104-77)",New,2/26/25,,,,,Urology,To Be Discontinued,,2/26/25
15364,"Tolterodine Tartrate Capsule, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Detrol LA, Capsule, Extended Release, 4 mg (NDC 58151-104-93)",New,2/26/25,,,,,Urology,To Be Discontinued,,2/26/25
15365,Tolterodine Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Detrol, Tablet, 1 mg (NDC 58151-098-91)",New,2/26/25,,,,,Urology,To Be Discontinued,,2/26/25
15366,Tolterodine Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Detrol, Tablet, 2 mg (NDC 58151-099-91)",New,2/26/25,,,,,Urology,To Be Discontinued,,2/26/25
15367,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 25 mg (NDC 0245-1071-30)",New,4/24/25,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/25
15368,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 50 mg (NDC 0245-1072-30)",New,4/24/25,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/25
15369,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 200 mg (NDC 0245-1073-30)",New,4/24/25,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/25
15370,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 100 mg (NDC 0245-1074-30)",New,4/24/25,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/25
15371,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 150 mg (NDC 0245-1075-30)",New,4/24/25,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/25
15372,Travoprost Solution/Drops,Sandoz Inc.,"Travatan Z, Solution/Drops, 2.5 mL (NDC 0781-6185-56)",New,3/18/25,,Business related decision to discontinue the product,,,Ophthalmology,To Be Discontinued,,3/18/25
15373,Travoprost Solution/Drops,Sandoz Inc.,"Travatan Z, Solution/Drops, 5 mL (NDC 0781-6185-75)",New,3/18/25,,Business related decision to discontinue the product,,,Ophthalmology,To Be Discontinued,,3/18/25
15374,Tretinoin Cream,"Mylan Pharmaceuticals Inc., a Viatris Company","Avita, Cream, .25 mg/1 g (NDC 0472-0117-20)",New,2/4/25,,,,,Dermatology,To Be Discontinued,,2/4/25
15375,Tretinoin Cream,"Mylan Pharmaceuticals Inc., a Viatris Company","Avita, Cream, .25 mg/1 g (NDC 0472-0117-45)",New,2/4/25,,,,,Dermatology,To Be Discontinued,,2/4/25
15376,Triamcinolone Acetonide Injection,"Harrow Eye, LLC","Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01)",Reverified,6/27/25,Limited Availability,Estimated duration: 12 months,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,
15377,Triamcinolone Hexacetonide Injection,Medexus,"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)",Reverified,6/27/25,Unavailable,,,Delay in shipping of the drug,Rheumatology,Current,,
15378,Ursodiol Tablet,"Teva Pharmaceuticals USA, Inc.","Ursodiol, Tablet, 250 mg (NDC 0591-2998-01)",New,3/28/25,,A business decision was made to discontinue manufacture of the drug.,,,Other,To Be Discontinued,,3/28/25
15379,Ursodiol Tablet,"Teva Pharmaceuticals USA, Inc.","Ursodiol, Tablet, 500 mg (NDC 0591-3005-01)",New,3/28/25,,A business decision was made to discontinue manufacture of the drug.,,,Other,To Be Discontinued,,3/28/25
15380,Valproate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)",Revised,7/23/25,Unavailable,Additional Lots scheduled to be available in the October 2025 timeframe.,,Demand increase for the drug,Neurology,Current,,
15381,Valproate Sodium Injection,"Fresenius Kabi USA, LLC","Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)",Reverified,9/2/25,Available,Checkwholesalers for inventory,,,Neurology,Current,,
15382,Varenicline Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Varenicline Tartrate, Tablet, .5 mg (NDC 0378-5089-73)",New,2/6/25,,Permanent discontinuation in the manufacturing of the drug,,,Analgesia/Addiction,To Be Discontinued,,2/6/25
15383,Varenicline Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Varenicline Tartrate, Tablet, 1 mg (NDC 0378-5090-73)",New,2/6/25,,Permanent discontinuation in the manufacturing of the drug,,,Analgesia/Addiction,To Be Discontinued,,2/6/25
15384,Varenicline Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Varenicline Tartrate, Tablet, 0.5mg/1mg  (NDC 0378-5091-85)",New,2/6/25,,Permanent discontinuation in the manufacturing of the drug,,,Analgesia/Addiction,To Be Discontinued,,2/6/25
15385,"Verapamil Hydrochloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Verelan, Capsule, Extended Release, 120 mg (NDC 0591-2880-01)",New,1/23/25,,,,,Cardiovascular,To Be Discontinued,,1/23/25
15386,"Verapamil Hydrochloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Verelan, Capsule, Extended Release, 180 mg (NDC 0591-2882-01)",New,1/23/25,,,,,Cardiovascular,To Be Discontinued,,1/23/25
15387,"Verapamil Hydrochloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Verelan, Capsule, Extended Release, 240 mg (NDC 0591-2884-01)",New,1/23/25,,,,,Cardiovascular,To Be Discontinued,,1/23/25
15388,"Verapamil Hydrochloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Verelan, Capsule, Extended Release, 360 mg (NDC 0591-2886-01)",New,1/23/25,,,,,Cardiovascular,To Be Discontinued,,1/23/25
15389,Voriconazole Tablet,Pfizer Inc.,"Vfend, Tablet, 50 mg (NDC 0049-3170-30)",New,7/28/25,,Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,,7/28/25
15390,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 500 mg (NDC 72786-101-01)",New,9/27/24,,,,,Hematology,To Be Discontinued,,9/27/24
15391,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 300 mg (NDC 72786-102-02)",New,9/27/24,,,,,Hematology,To Be Discontinued,,9/27/24
15392,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 300 mg (NDC 72786-102-03)",New,9/27/24,,,,,Hematology,To Be Discontinued,,9/27/24
15393,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 300 mg (NDC 72786-111-03)",New,9/27/24,,,,,Hematology,To Be Discontinued,,9/27/24
15394,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 300 mg (NDC 72786-111-02)",New,9/27/24,,,,,Hematology,To Be Discontinued,,9/27/24
15395,Zileuton Tablet,"Chiesi USA, Inc.","Zyflo, Tablet, 600 mg (NDC 10122-901-12)",New,4/1/25,,,,,Pulmonary/Allergy,To Be Discontinued,,4/1/25